Cumulative Index 1975, 1976, and 1977

Volumes 59, 60, and 61

Note: The volume year is in *italic* type. Page numbers of symposium and article titles are in **boldface** type.

SYMPOSIA

1975

January	RADIOLOGY IN INTERNAL MEDICINE
March	MALIGNANT DISEASE
May	RENAL METABOLISM
July	DISEASES OF THE LIVER
September	CURRENT CONCEPTS OF THYROID DISEASE
November	ADOLESCENT MEDICINE

1976

January	CARDIAC RHYTHM DISTURBANCES I
March	CARDIAC RHYTHM DISTURBANCES II
May	IMMUNOTHERAPY IN MALIGNANT DISEASE
July	TRACE ELEMENTS
September	ADVANCES IN HEMATOLOGY
November	GERIATRIC MEDICINE

1977

January	PREGNANCY
March	RHEUMATIC DISEASES
May	HYPERTENSION
July	PSYCHIATRY IN INTERNAL MEDICINE
September	ADVANCES IN TREATMENT OF CANCER
November	PULMONARY DISEASE

ABDOMEN, pain, in aged, *1976:* Nov., 1151
roentgen examination, *1975:* Jan., 122–124
in renal and adrenal hypertension, *1975:* Jan., **169–200**
Abdominal crisis, in sickle cell disease, *1976:* Sept., 934
Abortion, in adolescents, *1975:* Nov., 1424–1426
Abscess, liver, *1975:* March, 268–269
Absence seizures, in adolescents, *1975:* Nov., 1463
Acanthocytosis, *1976:* Sept., 924
Acetaminophen, *1977:* March, 407
hepatotoxicity, *1975:* July, 877–880
Acetazolamide, renal handling of, *1975:* May, 748
Acetohexamide, *1976:* Nov., 1205

Acetylsalicylic acid, *1977:* March, 294, 406–407
platelet response to, *1976:* Sept., 905–907
Achilles reflex time, in thyroidal disorders, *1975:* Sept., 1072
Achromotrichia, copper deficiency and, *1976:* July, 700–701
Acid(s), organic, renal excretion by nonionic diffusion, *1975:* May, **681–698**
Acid-base balance, assessment, *1977:* Nov., 1382–1386
in carcinoma, *1975:* March, **449–457**
in liver failure, *1975:* July, 929
renal metabolism and, *1975:* May, **781–795**
Acidosis, and alkalosis, in carcinoma, *1975:* March, 453–456
metabolic, renal ammonia production and, *1975:* May, 586, 599, **629–648**, 782–783
glutamine and, *1975:* May, **555–567**
renal carbon dioxide production in, *1975:* May, 511
renal gluconeogenesis and, *1975:* May, 786–788
renal glutamate and, *1975:* May, 673–675
Acne vulgaris, *1975:* Nov., 1474–1476
Acropachy, in Graves' disease, *1975:* Sept., 1181
Acrosclerosis, *1977:* March, 285
Actinomycin D, in malignant melanoma, *1977:* Sept., 1020
in Wilms' tumor, *1977:* Sept., 1045
Actinomycosis, *1977:* Nov., 1178
Addiction. See *Drug(s), abuse.*
Adenocarcinoma, of lung, *1975:* Jan., 101, 103; *1977:* Sept., 985, 987
Adenohypophysis, function, *1975:* Nov., 1290–1294
Adenoma, hepatocellular, *1975:* July, 1000–1002
Adenomatous goiter, surgery for, *1975:* Sept., 1258
Adenosine diphosphate, in platelet aggregation studies, *1976:* Sept., 881–884
Adenosine triphosphatase, in renal metabolism, thyroid hormone and, *1975:* May, **605–614**
Adipose tissue, thyroid function and, *1975:* Sept., 1127
Adolescents. See also *Puberty.*
adjustment reaction, pain complaint in, *1977:* July, 776
anemia in, *1975:* Nov., **1481–1488**
approach to, *1975:* Nov., **1281–1287**
as patients, *1977:* July, **839–854**
asthma, in, *1975:* Nov., 1489–1496
chronic disease in, *1975:* Nov., **1319–1328**
contraception for, *1975:* Nov., **1407–1418**
diabetes mellitus in, *1975:* Nov., **1349–1357**
drug abuse in, *1975:* Nov., **1439–1443**
medical complications, *1975:* Nov., **1445–1452**
Adolescents (*Continued*)
emotional problems in, *1975:* Nov., **1429–1437**
hepatitis in, *1975:* Nov., **1453–1460**
hormonal changes in, *1975:* Nov., **1289–1304**
hyperlipoproteinemias in, *1975:* Nov., **1359–1369**
hypertension in, *1975:* Nov., **1371–1383**
juvenile rheumatoid arthritis in, *1975:* Nov., 1497–1502
menstrual problems in, *1975:* Nov., **1385–1394**
nutrition of, *1975:* Nov., **1329–1336**
obesity in, *1975:* Nov., **1507–1516**
physical growth and development, *1975:* Nov., **1305–1318**
pregnancy in, *1975:* Nov., 1419–1427, 1487
psychosocial development, *1975:* Nov., 1319–1328
seizures in, *1975:* Nov., **1461–1473**
sexual development of, *1977:* July, 818
skin problems in, *1975:* Nov., **1473–1480**
spinal deformity in, *1975:* Nov., 1517–1525
systemic lupus erythematosus in, *1975:* Nov., 1502–1504
venereal disease in, *1975:* Nov., **1395–1405**
Adrenal glands, cortex, steroids. See *Corticosteroids.*
hormones. See under names of hormones.
in renal ammonia production, *1975:* May, 639–642
Adrenal hypertension, abdominal radiology in, *1975:* Jan., 192–197
Adrenalectomy, in metastatic breast cancer, *1975:* March, 428–429
Adrenalin. See *Epinephrine.*
Adrenergic stimulants, for asthma, *1977:* Nov., 1243–1245
Adrenocortical tumors, *1975:* Jan., 195
Adrenocorticosteroids. See *Corticosteroids.*
Adriamycin, *1976:* Sept., 959–961
in bronchogenic carcinoma, *1977:* Sept., 985
in metastatic breast cancer, *1977:* Sept., 969–972
in neuroblastoma, *1977:* Sept., 1060
in non-Hodgkin's lymphomas, *1976:* Sept., 1047–1051
in osteosarcoma, *1977:* Sept., 1034–1035
in soft tissue sarcomas, *1977:* Sept., 1040
in stomach cancer, *1977:* Sept., 996
Age, blood pressure and, *1977:* May, 469, 471, 513
Aged, medical care of (symposium), *1976:* Nov., **1059–1332**
Aging patient, *1977:* July, **855–866**
Air pollution, lung cancer and, *1975:* March, 322
Airways obstruction, chronic, *1977:* Nov., **1219–1228**
in sarcoidosis, *1977:* Nov., 1273–1274

Albinism, oculocutaneous, *1976:* Sept., 890
Albright's hereditary osteodystrophy, *1975:* Sept., 1265
Alcohol rhizotomy, *1975:* March, 481
Alcoholics Anonymous, *1977:* July, 805–806
Alcoholism, *1977:* July, **797–809**
in adolescents, *1975:* Nov., 1451
in pulmonary disease, *1977:* July, 752
liver disease with, *1975:* July, **909–918**, 959
Aldosteronism, roentgen signs, *1975:* Jan., 192–195
Alkaloids, pyrrolizidine, pulmonary hypertension from, *1977:* Nov., 1297–1303
Alkalosis, metabolic, renal ammonia production and, *1975:* May, 584, 591
renal carbon dioxide production in, *1975:* May, 511
renal citrate metabolism in, *1975:* May, 571–575
Alkylating agents, in metastatic breast cancer, *1977:* Sept., 969–972
Allergic alveolitis, extrinsic, *1977:* Nov., 1257
Allergic reactions, hepatic manifestations, *1975:* July, 901
Allergy, vasculitis from, *1977:* March, 254
Allpurinol, *1977:* March, 309
Alloxan, *1977:* Nov., 1321
Alpha-methyldopa, hepatotoxicity of, *1975:* July, 905
Altitude, pulmonary edema and, *1977:* Nov., 1322–1324
pulmonary vasculature and, *1977:* Nov., 1284
Alveolar air equation, *1977:* Nov., 1372
Alveolar cell carcinoma, roentgen signs, *1975:* Jan., 103, 108–109
Alveolar proteinosis, *1977:* Nov., 1253
Alveolitis, fibrosing, cryptogenic, *1977:* Nov., 1252
Amantadine hydrochloride, for influenza, *1977:* Nov., 1175
Amenorrhea, in adolescents, *1975:* Nov., **1385–1394**
lactational, *1977:* Jan., 157
Amikacin, *1977:* Sept., 1114
Amino acids, ketoanalogues, for hepatic encephalopathy, *1975:* July, 943
renal metabolism of, gluconeogenesis and, *1975:* May, **751–761**
Aminoglutethimide, in metastatic breast cancer, *1977:* Sept., 969
Aminoglycosides, *1977:* Nov., 1360
Aminorex, *1977:* Nov., 1299–1303
Ammonia, hepatic encephalopathy from, *1975:* July, 938
renal excretion, glutamine and, *1975:* May, **667–680**
renal production, acid-base changes and, *1975:* May, 781–785
acidosis and, *1975:* May, 629–648
glutamine and, *1975:* May, **555–567**
amino acid metabolism and, *1975:* May, 751–753
control of, *1975:* May, **583–593, 595–603**
Ammonia (*Continued*)
renal production, gluconeogensis and, *1975:* May, 788–791
Amphetamines, abuse, *1975:* Nov., 1449–1450
Amphotericin B, *1977:* Nov., 1175
Ampulla of Vater, carcinoma of, *1975:* March, **309–314**
Amylobarbital, liver disease and, *1975:* July, 890
Amyloidosis, *1977:* March, 223
in multiple myeloma, *1975:* March, 379, 383
of heart, in aged, *1976:* Nov., 1071
Amytriptyline (Elavil), *1977:* July, 894
Anaerobic pneumonias, *1977:* Nov., 1171
Anal sphincters, biofeedback control, *1977:* July, 908–909
Analgesics, hepatotoxicity of, *1975:* July, 903
nephropathy, *1977:* May, 615
parenchymal liver disease and, *1975:* July, 889–894
Androgen(s), in hyperthyroid men, *1975:* Sept., 1114–1117
in hyperthyroid women, *1975:* Sept., 1119–1120
pubertal changes, *1975:* Nov., 1297–1299
therapy, in metastatic breast cancer, *1975:* March, 426–427
Anemia, aplastic, in adolescents, *1975:* Nov., 1484–1485
infection in granulocytopenic patients, *1977:* Sept., **1101–1118**
cadmium and, *1976:* July, 760
copper deficiency and, *1976:* July, 656, 659, 688, 700
Diamond-Blackfan, *1976:* Sept., **945–958**
hemolytic, *1976:* Sept., **913–932**
in adolescents, *1975:* Nov., **1481–1488**
in systemic lupus, *1977:* March, 232
in thyroid disease, *1975:* Sept., **1133–1145**
megaloblastic, *1976:* Sept., 903
of pregnancy, *1977:* Jan., 167–170
sickle cell, *1976:* Sept., 926, **933–944**
Aneurysms, in elderly, *1976:* Nov., 1089
Angina pectoris, in aged, *1976:* Nov., 1063
Angiography, fluorescein, retinal, *1977:* May, 56
in jaundice, *1975:* Jan., 132
in liver disease, *1975:* July, 1021
renal, *1975:* March, 295–296
Aniridia, sporadic, *1977:* Sept., 1062
Ankylosing spondylitis, *1977:* March, 336, 340, 347–364
roentgen features, *1977:* March, 393, 395, 397, 399
Anorectal lesions, in granulocytopenic patient, *1977:* Sept., 1102
Antabuse. See *Disulfiram.*
Antiarrhythmic drugs, electroversion and, *1976:* March, 330
Antibiotics. See also specific drugs.
for septic arthritis, *1977:* March, 319

Antibiotics (*Continued*)
for urinary infection in pregnancy, *1977:* Jan., 95
in granulocytopenic patient, *1977:* Sept., 1103–1105
in hepatic encephalopathy, *1975:* July, 941
Antibody formation, levamisole-induced, *1976:* May, 523
Anticholinergics, in asthma, *1977:* Nov., 1248
Anticoagulant(s), *1976:* Sept., **855–869**
adverse drug reactions with, *1976:* Sept., 860
circulating, *1977:* Jan., 181
electroversion of arrhythmias and, *1976:* March, 337
for deep vein thrombosis, *1976:* Nov., 1095
in pulmonary hypertension, *1977:* Nov., 1315
Anticonvulsants, *1975:* Nov., 1465–1467
Antidepressants, tricyclic, *1977:* July, 894–896
Antidiuretic hormone, inappropriate secretion, *1975:* March, 433–435; *1976:* Nov., 1306
lung cancer and, *1977:* Nov., 1207
Anti-DNA and anti-ENA, *1977:* March, 381
Antigen(s). See also specific antigens.
recall, *1976:* May, 394
in therapy for skin cancer, *1976:* May, 399–403
tests for. See under specific antigens and tests.
tumor-specific, in leukemia, *1976:* Sept., 1022–1026
Antihypertensive drugs, *1977:* May, **675–698**
Antimalarial agents, *1977:* March, 411
Antimicrobial agents, in aged, *1976:* Nov., 1237
Antimitochondrial antibody, in hepatitis, *1975:* July, 871
Antineoplastic drugs, *1976:* Sept., **959–970**
Antinuclear antibody (ANA) titer, *1977:* March, 381
Anxiety, arrhythmias with, *1976:* Jan., 73
in cancer patient, *1977:* July, 745
in coronary patient, *1977:* July, 715, 717
in pulmonary disease, *1977:* July, 751
relaxation response in, *1977:* July, 935
Aorta, coarctation, *1977:* Jan., 36; May, **655–673**
thoracic, trauma to, roentgen signs, *1975:* Jan., 80–84
valvular disease, in aged, *1976:* Nov., 1069
Aphthous stomatitis, levamisole for, *1976:* May, 526
Aplastic anemia, in adolescents, *1975:* Nov., 1484–1485
infection in granulocytopenic patients, *1977:* Sept., **1101–1118**
Apresoline. See *Hydralazine.*
Arrhenoblastoma and thyroid adenoma, *1975:* Sept., 1270
Arrhythmias (symposia), *1976:* Jan., **1–209;** March, **211–386.** See also specific types.
after coronary occlusion, *1976:* Jan., **49–67**
biofeedback training for, *1977:* July, 915–919
classification of, *1976:* Jan., **3–48**
diagnosis of, computers in, *1976:* March, **291–298**
exercise stress testing in, *1976:* March, **313–324**
drugs for, electrophysiology of, *1976:* March, **213–232**
selection of, *1976:* March, 222–229
electroversion of, *1976:* March, **325–342**
hemodynamic consequences of, *1976:* Jan., **69–80**
Holter monitoring of, *1976:* March, **299–313**
in aged, *1976:* Nov., 1074–1076
in myocardial infarction, *1976:* March, **233–244**
in pregnancy, *1977:* Jan., 28
in Wolff-Parkinson-White syndrome, *1976:* Jan., 105–109
preexcitation, *1976:* Jan., **101–123**
sinus, *1976:* Jan., 3–5
Arterial infusion chemotherapy, regional, *1975:* March, **411–424**
Arteriography, in renovascular hypertension, *1975:* Jan., **174–187**
pulmonary, in thromboembolic disease, *1975:* Jan., **26–34**
Arteriosclerosis, *1976:* Nov., **1079–1092**
Arteriosclerosis obliterans, of lower extremities, *1976:* Nov., 1080–1086
Artery(ies), disease, degenerative, *1976:* Nov., 1079–1092
Arthritis, gonococcal, *1977:* March, 320–322
gouty, *1977:* March, 299–312
in elderly, *1976:* Nov., 1173–1189
infectious, *1977:* March, **313–329**
of Reiter's syndrome, *1977:* March, **365–376**
rheumatoid. See *Rheumatoid arthritis.*
juvenile, in adolescents, *1975:* Nov., 1497–1505
manganese deficiency and, *1976:* July, 730
septic, *1977:* March, 304, 315–320
Ascites, renal failure and, *1975:* July, 961–962
renal hypoperfusion and, *1975:* July, 958
Asparaginase, *1976:* Sept., 966–968; *1977:* March, 530
Aspergillosis, *1977:* Nov., 1178
Aspiration pneumonia, *1976:* Nov., 1131; *1977:* Jan., 118
Aspirin. See *Acetylsalicylic acid.*
Asthma. See *Bronchial asthma.*
Astrocytomas, *1977:* Sept., 1045
Asystole, baroreceptor response to, *1976:* Jan., 11
Ataractic drugs, *1977:* July, 898–904
Ataxia, newborn, manganese and, *1976:* July, 771

Atherosclerosis, cholesterol and, *1976:* March, 260
Athyreosis, *1975:* Sept., 1267
Athyreotic cretinism, *1977:* Jan., 72
Atrial echo, *1976:* Jan., 25, 27, 36
Atrial fibrillation, *1976:* Jan., 22–23, 71–72
electroversion of, *1976:* March, 332
hemodynamic changes, *1976:* Jan., 76
Atrial flutter, *1976:* Jan., 25, 28, 35
Atrial flutter-fibrillation, in Wolff-Parkinson-White syndrome, *1976:* Jan., 107
Atrial premature beats, *1976:* Jan., 27, 130, 131
Atrioventricular block, *1976:* Jan., 183–190
Mobitz, *1976:* Jan., 11
nodal, *1976:* Jan., 45
Atrioventricular nodal concealment, *1976:* Jan., 155–161
Atrioventricular nodal tachycardia, reciprocating, *1976:* Jan., 36–37
Atrium, mechanical activity, *1976:* Jan., 71
Atropine, in acute myocardial infarction, *1976:* March, 236
Aurothioglucose (Solganal), *1977:* March, 413
Australia antigen, *1975:* July, **835–842**
clinical significance of, *1975:* July, **849–855**
Autoantibody response, *1977:* March, 208–212
Autoimmune diseases, genetic mechanisms, *1977:* March, 341–343
immunologic and viral factors, *1977:* March, **205–215**
Autoimmune hemolytic anemia, *1977:* Jan., 177
Autoimmunity, in Hashimoto's thyroiditis, *1975:* Sept., 1166–1171
in hepatitis, *1975:* July, **869–876**
in subacute thyroiditis, *1975:* Sept., 1165
Aventyl. See *Nortriptyline.*
Avimanganin, *1976:* July, 723–725
5-Azacytidine (Aza-C), *1976:* Sept., 968
Azarabine, *1977:* March, 430
Azaserine, *1977:* March, 420
Azathioprine, *1977:* March, 293, 420–422, 425–431
in ITP, *1976:* Sept., 973–974
Azotemia, in fulminant hepatic failure, *1975:* July, 928

BACILLUS Calmette-Guerin, (BCG), as immunomodular, *1976:* May, 474–475
enhanced tumor growth with, *1976:* May, 505
for leukemia, *1976:* Sept., 1029–1032, 1033–1034
for lymphoma, *1976:* May, 450–451
for malignant melanoma, *1977:* Sept., 1018
as systemic adjunct to surgery, *1976:* May, **431–439**
imidazole carboxamide with, *1976:* May, 443–445
intralesional injection, *1976:* May, **419–430**
Bacillus Calmette-Guerin (BCG) (*Continued*)
hazards and complications of, *1976:* May, 425–426, 436–437, **499–509**
immunopotentiating effects of, *1976:* May, 401–408
in metastatic breast cancer, *1977:* Sept., 973–975
Bacteremia, in aged, *1976:* Nov., 1235
Bacterial diarrhea, *1977:* March, 325–326
Bacterial infection, drug abuse and, *1975:* Nov., 1446–1447
in leukemia, *1975:* March, 367–369; *1976:* Sept., 993
Bacterial peritonitis, in cirrhosis, *1975:* July, **963–981**
Bacterial pneumonias, *1977:* Nov., 1164–1172. See also specific types.
Bacteriuria, asymptomatic, in aged, *1976:* Nov., 1232
in pregnancy, *1977:* Jan., 93
Bacteroides fragilis, pneumonia from, *1977:* Nov., 1172
Bamboo spine, *1977:* March, 351
Barbiturates, abuse, *1975:* Nov., 1449
for seizures in adolescents, *1975:* Nov., 1467
liver disease and, *1975:* July, 889
Basal cell carcinoma, immunotherapy in, *1976:* May, 391, 399–402
BCG. See *Bacillus Calmette-Guerin.*
BCNU, C. parvum immunomodulation with, *1976:* May, 516
in brain tumors, *1977:* Sept., 1048–1050
Beclomethasone, *1977:* Nov., 1247
Behavior modification, in obesity, *1977:* July, 792–793
in sexual disorders, *1977:* July, 820–821
Behavioral neurology, *1977:* July, **723–736**
Benzbromarone, *1977:* March, 309
Benzodiazepines, *1975:* Nov., 1469
liver disease and, *1975:* July, 891
smoking and, *1974:* Sept., 1146
Bernard-Soulier syndrome, platelet aggregation in, *1976:* Sept., 896
Berylliosis, *1977:* Nov., 1259–1261
Beta-adrenergic blocking agents, in hyperthyroidism, *1975:* Sept., 1196–1199
Beta-hemolytic streptococcus, group B, *1977:* Jan., 149
Bethanidine, *1977:* May, 684
Bigeminy, intermittent, *1976:* Jan., 137
law of, *1976:* Jan., 38
Biguanides, in aged, *1976:* Nov., 1202
Bile acid metabolism, in cholelithiasis, *1975:* July, 1028
Bile duct, adenoma, *1975:* July, 1002
cystadenoma, *1975:* July, 1004
surgery, extrahepatic obstruction after, *1975:* July, 828
Biliary cirrhosis, primary, *1975:* July, 820–821
Biliary tract, diseases of, cholestasis in, *1975:* July, 818
pancreatography in, *1975:* March, **239–246**
obstruction, *1976:* Nov., 1154
after bile duct surgery, *1975:* July, 828

Bilirubin, metabolism, inborn errors of, *1975:* July, **803–816**
overproduction, postoperative, *1975:* July, 823–825
tests, *1975:* July, 1016–1018
Biofeedback techniques, in cardiovascular disorders, *1977:* July, **913–928**
in gastrointestinal disorders, *1977:* July, **907–912**
Biogenic amines, hepatic encephalopathy, *1975:* July, 938
Biopsy, lung, *1975:* Jan., 112–115; March, 280–281
needle, in thyroid disorders, *1975:* Sept., 1226–1228
pleural, *1977:* Nov., 1350
skin, in malignant melanoma, *1975:* March, 303
Bladder, carcinoma of, roentgen signs, *1975:* Jan., 217
trauma to, hematuria with, *1975:* Jan., 212, 217
Blastomycosis, *1977:* Nov., 1177
Bleeding. See *Hemorrhage.*
Bleomycin, *1976:* Sept., 961–963
in non-Hodgkin's lymphomas, *1976:* Sept., 1047, 1048–1051
pulmonary toxicity, *1977:* Nov., 1354
Blindness, psychogenic, *1977:* July, 729
Blood, coagulation. See *Coagulation.*
disorders, (symposium), *1976:* Sept., **853–1052**
in pregnancy, *1977:* Jan., **165–199**
elements. See under specific names.
lipids. See *Lipids.*
platelets. See *Platelets.*
pressure, autoregulation, *1977:* May, 675
in children, *1977:* May, **487–493**
increased. See *Hypertension.*
renal prostaglandins and, *1975:* May, **713–733**
transfusion, pulmonary edema after, *1977:* Nov., 1332
volume, in pregnancy, *1977:* Jan., 18
Body, composition, pubertal changes, *1975:* Nov., 1305–1306
image, development of, *1977:* July, 840–842
preoccupation, in pulmonary disease, *1977:* July, 752
Bone, abnormalities, copper deficiency and, *1976:* July, 691
aseptic necrosis, sickle cell disease and, *1976:* Sept., 936
marrow, depression, in hypothyroidism, *1975:* Sept., 1137
failure, platelet transfusion for, *1977:* Sept., 1135
in chronic granulocytic leukemia, *1976:* Sept., 1002–1003
transplant, infection after, *1977:* Sept., **1101–1118**
Borderline hypertension, *1977:* May, **495–511**
Bowel. See also *Intestine(s).*
disease, in pregnancy, *1977:* Jan., 135
inflammatory, delayed puberty and, *1975:* Nov., 1344
Bowel (*Continued*)
habits, in aged, *1976:* Nov., 1144
irritable, biofeedback in, *1977:* July, 911
Bowen's disease, *1975:* March, 474
Bradycardia, sinus, *1976:* Jan., 5
hemodynamic changes, *1976:* Jan., 75
in myocardial infarction, *1976:* March, 240
Brain dopamine, manganese and, *1976:* July, **729–738**
Brain syndrome, organic, *1976:* Nov., **1298–1308**
Brain tumors, *1975:* March, 405; *1977:* Sept., **1045–1051**
Breast, carcinoma of, *1976:* Nov., 1245
adjuvant chemotherapy in, *1977:* Sept., **953–965**
advances in treatment, *1977:* Sept., 946
chemoimmunotherapy for, *1976:* May, 445
immunotherapy for, modified tumors cells in, *1976:* May, **551–565**
metastatic, *1975:* March, **425–430**
chemotherapy for, *1977:* Sept., 969–972
metastatic, immunotherapeutic approaches to, *1976:* May, 406–408
management of, *1977:* Sept., **967–978**
primary, *1975:* March, **285–292**
Breast feeding, *1977:* Jan., **153–163**
Breathing, problems in, *1977:* Nov., 1220
Bronchial asthma, in adolescents, *1975:* Nov., **1489–1496**
in pregnancy, *1977:* Jan., 122
pathophysiology, *1977:* Nov., **1229–1238**
therapy, *1977:* Nov., **1239–1250**
Bronchial brushing, *1975:* March, 278–279
Bronchiectasis, *1977:* Jan., 121
Bronchitis, in aged, *1976:* Nov., 1123
in pregnancy, *1977:* Jan., 117, 123
Bronchodilators, *1977:* Nov., 1220
Bronchogenic carcinoma, *1977:* Sept., **979–989;** Nov., 1212
epidermoid, chemoimmunotherapy for, *1976:* May, 448
hypercalcemia with, *1075:* March, 441
roentgen staging, *1975:* Jan., 115–117
Bronchography, in detection of lung cancer, *1975:* Jan., 111–112
Bronchoscopy, fiberoptic, *1977:* Nov., 1208
lung biopsy via, *1975:* March, 278
Bronchospasm, *1977:* Nov., 1220
Brush biopsy, of lung, *1975:* Jan., 114–115
Brush border membranes, renal, *1975:* May, 615
Bundle branch block, *1976:* Jan., 47, 161–163, 175–183
Bundle branch re-entry, *1976:* Jan., 25
Burkitt's lymphoma, *1976:* Sept., 1044; *1977:* Sept., **1073–1082**
serotherapy of, *1976:* May, 613–614
Busulfan (Myleran), in leukemia, *1976:* Sept., 1007–1008
pulmonary toxicity, *1977:* Nov., 1353
Butyrophenones, *1977:* July, 898–904

CADMIUM, biology of, *1976:* July, **759–769**
drug metabolism and, *1976:* July, 821–824
Calcium, requirements in pregnancy, *1977:* Jan., 10–11
Calculus(i), renal, in aged, *1976:* Nov., 1114
roentgen signs, *1975:* Jan., 205, 207
Caloric balance, positive. See *Obesity.*
Calorigenesis, thyroid function and, *1975:* Sept., 1128
Caplan's syndrome, *1977:* March, 219
Capreomycin, *1977:* Nov., 1200
Carbamazepine (Tegretol), *1975:* Nov., 1468
Carbenicillin, in granulocytopenic patient, *1977:* Sept., 1105–1109
platelet response to, *1976:* Sept., 907
Carbohydrate(s), metabolism, chromium and, *1976:* July, **739–744**
Carbon dioxide, renal production, *1975:* May, **507–522**
glucose and, *1975:* May, 544–546
lactate and, *1975:* May, 547–550
Carcinoembryonic antigen, *1976:* Nov., 1249
Carcinoid tumors, *1975:* March, 401
Carcinoma. See also under specific organs and types.
anatomic extent of, *1977:* Sept., 947
combination chemotherapy for, *1977:* Sept., 949
cutaneous manifestations, *1975:* March, **471–479**
drug therapy in, *1976:* Sept., **959–970**
fluid and electrolyte problems in, *1975:* March, **449–457**
growth kinetics of solid tumors, *1975:* March, **339–346**
hypercalcemia in, *1975:* March, **441–447**
in aged, *1976:* Nov., **1241–1251**
management, psychological aspects of, *1977:* July, **737–748**
pain of, neurosurgery for, *1975:* March, **481–485**
patient, immune evaluation of, *1976:* May, **623–639**
prognostic factors in, importance of, *1977:* Sept., 948
psychosocial aspects, *1977:* Sept., **1147–1155**
therapy (symposium), *1977:* Sept., **943–1157**
immunologic approach, *1975:* March, **327–337**
Cardiac. See also *Heart.*
Cardiac arrhythmia. See *Arrhythmia(s).*
Cardiac catheterization, iatrogenic complications, *1975:* Jan., 84–86
Cardiac conduction, concealed, *1976:* Jan., **149–173**
disturbances, *1976:* Jan., 44–47
exercise-induced, *1976:* March, 318
Cardiac conduction system, pacemaker cells, ectopic beats and, *1976:* Jan., 7–13
Cardiac emergencies, rapid response systems for, *1976:* March, **283–290**
Cardiac output, in borderline hypertension, *1977:* May, 498
Cardiac rhythm disturbance (symposia), *1976:* Jan., **1–209;** March, **211–386.** See also *Arrhythmia(s).*
Cardiac tamponade, *1975:* Jan., 65–67, 69
Cardiogenic shock, in aged, *1976:* Nov., 1065
Cardiomyopathy, peripartal, *1977:* Jan., 35
Cardiopulmonary resuscitation, emergency system for, *1976:* March, **283–290**
Cardiovascular disorders, biofeedback training for, *1977:* July, **913–928**
in pregnancy, *1977:* Jan., **17–41**
thyroid hormone therapy in, *1975:* Sept., 1159–1160
Cardiovascular system, hemodynamic changes during arrhythmias, *1976:* Jan., **69–80**
hyperthyroidism and, *1975:* Sept., **1193–1201**
post-traumatic shunts, *1975:* Jan., 71, 78
roentgen evaluation in chest trauma, *1975:* Jan., **65–93**
thyroid function and, *1975:* Sept., 1125–1126
Catecholamine-thyroid interactions, *1975:* Sept., **1123–1131**
Catechols, *1977:* Nov., 1243
Catheterization, cardiac, iatrogenic complications, *1975:* Jan., 84–86
Cavernous hemangioma, of liver, *1975:* July, 1007–1008
Central nervous system. See *Nervous system, central.*
Cephalothin, in granulocytopenic patient, *1977:* Sept., 1106–1109
Cerebral autoregulation, *1977:* May, 567
Cerebrovascular disease, *1976:* Nov., 1086–1089
in hypertension, *1977:* May, **565–580**
Ceruloplasmin, *1976:* July, 689
Chemical inhalation pneumonia, roentgen signs, *1975:* Jan., 50, 52
Chemoimmunotherapy, in human solid tumors, *1976:* May, **441–462**
in leukemia, *1976:* May, **539–549**
Chemotherapy. See also specific agents and disorders.
combination, present status, *1977:* Sept., 949
for cancer, growth kinetics of solid tumors and, *1975:* March, **339–346**
for solid tumors, *1975:* March, **399–409**
regional arterial infusion, *1975:* March, **411–424**
Chenodeoxycholic acid, for cholesterol gallstones, *1975:* July, **1025–1033**
Chest, pain, of myocardial infarction, *1977:* July, 711–715
roentgen examination, in pulmonary thromboembolic disease, *1975:* Jan., 5–15
technical factors, *1975:* Jan., 97–99
trauma, roentgen evaluation of cardiovascular system, *1975:* Jan., **65–93**
roentgen evaluation of respiratory system, *1975:* Jan., **37–64**

Children. See also *Adolescents; Infant(s).*
acute leukemia in, *1976:* Sept., **987–1000**
blood pressure in, *1977:* May, **487–493**
Chlamydia, genital infection with, *1975:* Nov., 1401
Chlorambucil, *1977:* March, 221, 293, 420–422, 427, 433
in non-Hodgkin's lymphoma, *1976:* Sept., 1046–1048
Chloramphenicol, *1977:* March, 420
Chlordiazepoxide (Librium), *1977:* Nov., 1326
liver disease and, *1975:* July, 891
Chlorothiazide, site and mode of action, *1975:* May, 735–741
Chlorphentermine (Lucofen SA), *1977:* Nov., 1301
Chlorpromazine (Thorazine), *1977:* July, 898
Cholangiocellular tumors, benign, *1975:* July, 1002–1004
Cholangiography, *1975:* Jan., 131–132
in liver disease, *1975:* July, 1020
operative, *1975:* Jan., 134–139
Cholangioma, benign, *1975:* July, 1002
Cholecystitis, postoperative, acute, *1975:* July, 829
Cholecystography, *1975:* Jan., 125
Choledocholithiasis, *1976:* Nov., 1155
Cholelithiasis, chenodeoxycholic acid for, *1975:* July, **1025–1033**
Cholestasis, intrahepatic, drug-induced, *1977:* Jan., 131
familial, *1975:* July, 815
postoperative, *1975:* July, 826
metabolic disorders and, *1975:* July, 920, 923
Cholestatic jaundice, *1975:* July, **817–821**
Cholesterol, sudden coronary death and, *1976:* March, 254–259, 260
Cholesterol gallstones, *1975:* July, **1025–1033**
Chondrocalcinosis, *1977:* March, 398
Chondrodystrophy, in chicks, manganese deficiency and, *1976:* July, 730
Chondroitin sulfate, biosynthesis of, manganese and, *1976:* July, 716
Chorea, in aged, *1976:* Nov., 1321
Chromium, carbohydrate metabolism and, *1976:* July, **739–744**
Chromones, for asthma, *1977:* Nov., 1245
Chromosomal disorders, thyroid dysfunction with, *1975:* Sept., 1270
Chrysotherapy, *1977:* March, 412–414
Cigarette smoking. See *Smoking.*
Cirrhosis, after intestinal bypass, *1975:* July, 827
alcoholic, *1975:* July, 910, 912–913
arterial hypoxemia in, *1975:* July, 984
bacterial peritonitis in, *1975:* July, **963–981**
biliary, primary, *1975:* July, 820–821
chronic, renal failure and, *1975:* July, 960–961
cryptogenic cholestasis and, *1975:* July, 819–820
cyanosis of, *1975:* July, **983–987**
Cirrhosis (*Continued*)
portal hypertension with, *1975:* July, 945–947
pseudotumor of, differentiation, *1975:* March, 255, 257
Citrate, renal metabolism of, *1975:* May, 515–516, 519, **569–582**
Citrovorum factor, in osteosarcoma, *1977:* Sept., 1034
Claudication, *1976:* Nov., 1080
Clonazepam, *1975:* Nov., 1469
Clonidine, *1977:* May, 678–679
Clostridium perfringens neuraminidase, *1977:* Sept., 1085
Clotting, blood. See *Coagulation.*
CMF combination chemotherapy, in metastatic breast cancer, *1977:* Sept., 969–971
CNS. See *Nervous system, central.*
Coagulation, disorders of, fibrinolysis and *1976:* Sept., 874
in pregnancy, *1977:* Jan., 179
Coagulopathy, *1976:* Nov., 1282
Coarctation, aortic, *1977:* Jan., 35; May, **655–673**
Coccidioidomycosis, *1977:* Jan., 119; Nov., 1176
Cogan's syndrome, *1977:* March, 256
Colchicine, *1977:* March, 294, 307, 310, 411, 420
Cold intolerance, thyroid function and, *1975:* Sept., 1128
Colistin, *1977:* Nov., 1360
Colitis, ischemic, *1976:* Nov., 1147
Collagen, crosslinking, copper deficiency and, *1976:* July, 694
in platelet aggregation studies, *1976:* Sept., 881–884
Colon, cancer of, *1976:* Nov., 1247
volvulus, *1976:* Nov., 1152
Colorectal cancer, *1975:* March, **347–361;** *1977:* Sept., 991–994
chemoimmunotherapy for, *1976:* May, 446–448
chemotherapy for, *1975:* March, 401–402
Coma, myxedema, thyroid hormone therapy in, *1975:* Sept., 1160
Compliance, improving, *1977:* July, **879–889**
of adolescents, *1977:* July, 847
Confidentiality, *1977:* July, 870
Congenital anomalies, trace elements and, *1976:* July, **771–778**
zinc deficiency and, *1976:* July, 677–678
Congenital heart disease, in aged, *1976:* Nov., 1070
Congestive heart failure, *1976:* Nov., 1076; *1977:* May, 583–587, 658
perfusion lung scan in, *1975:* Jan., 17
Conjunctivitis, *1977:* March, 365
Connective tissue, aging, *1976:* Nov., 1174
amine oxidases, *1976:* July, 689
disorders, in Sjögren's syndrome, *1977:* March, 279
mixed, *1977:* March, 252, 284
Consent, informed, *1977:* July, 871
Constipation, in aged, *1976:* Nov., 1144

Contact dermatitis, *1975:* Nov., 1477
Contraception, for adolescents, *1975:* Nov., **1407–1418**
Contraceptives, oral, hepatotoxicity, *1975:* July, 904
  pulmonary hypertension and, *1977:* Nov., 1361
Conversion reaction, *1977:* July, 775–776
Convulsive seizures, in adolescents, *1975:* Nov., **1461–1473**
  pulmonary edema after, *1977:* Nov., 1327
Copper, abnormalities, diagnosis of, *1976:* July, **655–660**
  biochemistry of, *1976:* July, **687–703**
  deficiency, congenital anomalies from, *1976:* July, 775
  drug metabolism and, *1976:* July, 818–821
  endocrine function and, *1976:* July, 781, 783–785
  metabolism, heredity and environment and, *1976:* July, **705–712**
  infection and, *1976:* July, 840
  toxicity, *1976:* July, 706–710
Copper-wire arteries, retinal, *1977:* May, 551
Cor pulmonale, *1976:* Nov., 1073
Coronary artery disease, psychological factors, *1977:* July, **711–721**
Coronary care unit, mobile, *1976:* March, 284
Coronary heart disease, death from, prevention of, *1976:* March, **245–282**
  hypertension and, *1977:* May, 473–475
Coronary occlusion, arrhythmias after, *1976:* Jan., **49–67**
Corticosteroids, *1977:* March, 238, 269, 285, 307, 316, 414–415, 420, 433, 434
  effects on trace metal metabolism, *1976:* July, 791–792
  for asthma, *1975:* Nov., 1494; *1977:* Nov., 1246
  in chronic airflow obstruction, *1977:* Nov., 1221
  in fulminant hepatic failure, *1975:* July, 932
  in sarcoidosis, *1977:* Nov., 1270
  liver injury from, *1975:* July, 901, 903
  pulmonary toxicity, *1977:* Nov., 1356
Cortisone, in non-Hodgkin's lymphomas, *1976:* Sept., 1047
Corynebacterium parvum, as immunomodulator, *1976:* May, **511–523**
  in metastatic breast cancer, *1977:* Sept., 973–975
  side effects of, *1976:* May, 521–522
Cotton-wool patches, retinal, *1977:* May, 555
Counseling, in sexual disorders, *1977:* July, 821
Cranial metastases, surgery in, *1975:* March, 487–491
CREST syndrome, *1977:* March, 286
Cretinism, athyreotic, *1977:* Jan., 72
  thyroid hormone therapy in, *1975:* Sept., 1160
Crigler-Najjar syndrome, *1975:* July, 808–809
Crohn's disease, *1976:* Nov., 1146; *1977:* Jan., 135
  arthritis with, *1977:* March, 338
Cromolyn sodium, for asthma, *1975:* Nov., 1494; *1977:* Nov., 1245
Crotolaria fulva, pulmonary hypertension from, *1977:* Nov., 1295
Crotalaria laburnoides, pulmonary hypertension from, *1977:* Nov., 1297
Crotolaria spectabilis, pulmonary hypertension from, *1977:* Nov., 1294
Cryoglobulinemia, *1977:* March, 222
Cryptococcosis, *1977:* Nov., 1177
Cryptothyroidism, *1975:* Sept., 1267
Coumarin, *1976:* Sept., 859–861
Cuproenzymes, *1976:* July, 688–691
Cushing's syndrome, *1975:* Jan., 195; March, 431–432
  lung cancer and, *1977:* Nov., 1207
Cyanosis, in cirrhosis, *1975:* July, **983–987**
Cyclophosphamide (Cytoxan), *1977:* March, 221, 293, 420, 422, 425–431
  C. parvum with, *1976:* May, 516
  in bronchogenic carcinoma, *1977:* Sept., 981–982
  in ITP, *1976:* Sept., 974
  in metastatic breast cancer, *1977:* Sept., 969–972
  in non-Hodgkin's lymphomas, *1976:* Sept., 1046–1048
  in osteosarcoma, *1977:* Sept., 1034
  neuraminidase-treated leukemic cells and, *1977:* Sept., 1089
Cycloserine, *1977:* Nov., 1199, 1200
Cyproheptadine (Periactin), obesity and, *1977:* July, 791
Cyst, renal, roentgen signs, *1975:* Jan., 223–225, 228–229
Cystadenoma, bile duct, *1975:* July, 1004
Cystathionine, urinary, in neuroblastoma, *1977:* Sept., 1057
Cystic fibrosis, iodide-sensitivity with, *1975:* Sept., 1082
Cytochrome c oxidase, *1976:* July, 690
Cytomegalovirus infection, genital, *1975:* Nov., 1402; *1977:* Jan., 142
Cytoxan. See *Cyclophosphamide.*

DACTYLITIS, sickle cell, *1976:* Sept., 934
Darvon. See *Propoxyphene.*
Daunomycin, *1977:* Sept., 1060
Deaf mutism, familial goiter and, *1975:* Sept., 1266
Death, coronary, sudden, prevention of, *1976:* March, **245–282**
Deep vein thrombosis, *1976:* Sept., 863; *1977:* Nov., 1313
Defibrillation, electrical, *1976:* March, 326–335
Defibrination syndrome, *1976:* Sept., **871–880**
Degenerative arterial disease, *1976:* Nov., 1079–1092

Deglutition, disorders, in aged, *1976:* Nov., 1141–1144
Dehalogenase defect, *1975:* Sept., 1266
Dehydration, in carcinoma, *1975:* March, 452–453
Depression, in cancer patient, *1977:* July, 745
in elderly, *1977:* July, 861–863
in pulmonary disease, *1977:* July, 751
pain and, *1977:* July, 776
DeQuervain's thyrciditis, *1975:* Sept., 1163–1166, 1259
Dermatitis, contact, *1975:* Nov., 1477
seborrheic, *1975:* Nov., 1476
Dermatologic disorders, in adolescents, *1975:* Nov., **1473–1480**
Dermatomyositis, *1977:* March, 432, **439–451**
Dermatophytoses, *1975:* Nov., 1478
Desipramine (Norpramin, Pertofan), *1977:* July, 894
Diabetes, as model for aging, *1976:* Nov., 1209–1211
Diabetes mellitus, in adolescents, *1975:* Nov., **1349–1357**
in aged, *1976:* Nov., **1191–1208**
in pregnancy, *1977:* Jan., **43–66**
Diamond-Blackfan anemia, *1976:* Sept., **945–958**
Diaphragm, injuries to, roentgen signs, *1975:* Jan., 59, 60
Diarrhea, bacterial, arthritis and, *1977:* March, 325–326
in aged, *1976:* Nov., 1146
Diazepam (Valium), liver disease and, *1975:* July, 891
Diazoxide, *1977:* May, 619, 689
Dibenzoxazepine (Loxitane), *1977:* July, 899
Dichlorphenamide, renal handling of, *1975:* May, 746–747
Diet, in diabetics, *1976:* Nov., 1197–1208
diabetic, pregnant, *1977:* Jan., 26, 69
osteoporosis and, *1976:* Nov., 1219
pulmonary hypertension and, *1977:* Nov., 1294–1303
Diffusion, non-ionic, renal excretion by, *1975:* May, **681–698**
Digitalis, bigeminy from, *1976:* Jan., 38
electroversion of arrhthymias and, *1976:* March, 337
in acute myocardial infarction, *1976:* March, 238
intoxication, atrial fibrillation with, *1976:* Jan., 22
serum assay, clinical applications, *1976:* Jan., **193–207**
Dihydroindolone (Moban), *1977:* July, 899
Dilantin. See *Diphenylhydantoin.*
Dinitrochlorobenzene (DNCB) immunotherapy, for malignant disease, *1976:* May, 391–394
for myocosis fungoides, *1976:* May, 405
for xeroderma pigmentosum, *1976:* May, 397–399
levamisole and, *1976:* May, 524–525
Diphenylhydantoin, *1975:* Nov., 1467
Diphenylhydantoin (*Continued*)
electrophysiologic aspects, *1976:* March, 219
for arrhythmias, *1976:* March, 224
pulmonary reactions, *1977:* Nov., 1362
Diplopia, *1977:* March, 267
Disease, concept of, *1977:* July, **703–710**
Disodium cromoglycate. See *Cromolyn sodium.*
Disseminated intravascular coagulation, *1977:* Jan., 184
Disulfiram (Antabuse), *1977:* July, 805
Diuretics, *1977:* May, 692
hepatic encephalopathy and, *1975:* July, 939
in adolescents, *1975:* Nov., 1381
in pregnancy, *1977:* Jan., 27
sulfonamide-derived, *1975:* May, **735–750**
Dizziness, in elderly, *1976:* Nov., 1086
DMO (5,5-dimethyl-2,4-oxazolidine-dione), renal excretion, *1975:* May, 684–687
Down's syndrome, hypothyroidism with, *1975:* Sept., 1270
Doxepin (Sinequan), *1977:* July, 894
Drowning, *1977:* Nov., 1330
Drug(s). See also specific names and types of drugs, as *Antibiotics.*
abuse, hepatitis and, *1975:* July, **843–848**
in adolescents, *1975:* Nov., **1439–1443**
medical complications, *1975:* Nov., **1445–1452**
skin infection with, *1975:* Nov., 1479
allergic reactions to, hepatic, *1975:* July, 881–883
antiarrhythmic, electrophysiology of, *1976:* March, **213–232**
electroversion and, *1976:* March, 330
hemodynamic effects, *1976:* Jan., 73
selection of, *1976:* March, 222–229
anticonvulsant, *1975:* Nov., 1466–1467
antihypertensive, *1977:* May, **675–698**
antineoplastic, *1976:* Sept., **959–970**
as cause of obesity, *1977:* July, 791–792
hepatitis from, *1975:* July, 871
hepatotoxicity of, *1975:* July, **877–885, 897–907,** 940
immunosuppressive. See also *Immunotherapy.*
in rheumatic diseases, *1977:* March, **405–418**
intrahepatic cholestasis and, *1977:* Jan., 131
metabolism, parenchymal liver disease and, *1975:* July, **887–896**
trace elements and, *1976:* July, 813–830
neuroleptic, *1977:* July, 898–904
overuse, in alcoholism, *1977:* July, 804–805
platelet abnormalities due to, *1976:* Sept., 905–908
psychotropic, *1977:* July, **891–905**
in cancer patients, *1977:* July, 745–747
in elderly, *1977:* July, 865
pulmonary reactions to, *1977:* Nov., **1353–1369**

Drusen, *1977:* May, 557
DTIC (Imidazole carboxamide), *1976:* Sept., 965–966
for malignant melanoma, *1976:* May, 443–445; *1977:* Sept., 1020
in neuroblastoma, *1977:* Sept., 1060
in soft tissue sarcomas, *1977:* Sept., 1040
Dubin-Johnson syndrome, *1975:* July, 812–814
Dwarfism, hypogonadal, zinc deficiency and, *1976:* July, 676–677
Dynamic psychotherapies, in sexual disorders, *1977:* July, 820
Dysfunctional uterine bleeding, in adolescents, *1975:* Nov., 1390–1393
Dyspareunia, *1977:* July, 816
Dysphagia, in aged, *1976:* Nov., 1141–1144
Dyspnea, in pregnancy, *1977:* Jan., 115

E-ROSETTES, in bioassay for thymosin, *1976:* May, 595
Eales disease, *1977:* March, 256
Eclampsia, *1977:* Jan., 96
Echo, atrial, *1976:* Jan., 25, 27, 36
sinus, *1976:* Jan., 25, 28
Ecologic stress, hypertension and, *1977:* May, 533–535
Ectopic beats, *1976:* Jan., 7
Elastic pulmonary artery, *1977:* Nov., 1279
Elastin crosslinks, copper deficiency and, *1976:* July, 695
Elderly, health care of, *1976:* Nov., **1059–1332**
hypertension in, *1977:* May, **513–529, 643–653**
Electrolyte(s). See also *Fluids and electrolytes.*
imbalance, in liver failure, *1975:* July, 929
Electroversion of cardiac dysrhythmias, *1976:* March, **325–342**
drug therapy with, *1976:* March, 337–338
Embolism, pulmonary, *1976:* Nov., 1098–1100; *1977:* Nov., **1309–1318**
roentgen evaluation, *1975:* Jan., **3–36**
Emergencies, cardiac, rapid response systems for, *1976:* March, **283–290**
Emotional problems, in adolescents, *1975:* Nov., **1429–1437**
Emotional stress, hypertension and, *1977:* May, 531–535
in pulmonary disease, *1977:* July, 751–754
myocardial infarction and, *1977:* July, 720
Emphysema, *1976:* Nov., 1123
cadmium and, *1976:* July, 766–767
in pregnancy, *1977:* Jan., 123
mediastinal, *1975:* Jan., 70
perfusion lung scan in, *1975:* Jan., 20, 21, 25
Encephalopathy, hepatic, *1975:* July, 927, **937–944**
hypertensive, *1977:* May, 567, 569–571
in cancer patient, *1977:* July, 744
Endocarditis, infectious, *1976:* Nov., 1227–1229
Endocrine system, manipulation, in metastatic breast cancer, *1977:* Sept., 967–969
trace metals and, *1976:* July, **779–797**
Energy requirements, of pregnancy, *1977:* Jan., 4
Enterohepatic circulation, *1975:* July, 817–818
Enthesopathy, *1977:* March, 349
Environment, hypertension and, *1977:* May, **531–545**
Enzymes, copper-dependent, *1976:* July, 688–691
gastrointestinal. See specific enzymes, as *Pepsin.*
serum, in thyroid dysfunction, *1975:* Sept., 1073
Ephedrine, *1975:* Nov., 1494; *1977:* Nov., 1243–1244
Epidermoid carcinoma, of lung, *1977:* Sept., 985
Epilepsy, *1977:* July, 725–728
in adolescents, *1975:* Nov., **1461–1473**
Epinephrine, for asthma, *1975:* Nov., 1493–1494; *1977:* Nov., 1246–1247
in platelet aggregation studies, *1976:* Sept., 881–884
Epstein-Barr virus, *1977:* Sept., 1074
Equilibrium reactions, in renal ammonia production, *1975:* May, **595–603**
Erythema nodosum, sarcoidosis and, *1977:* Nov., 1267
Erythrocytes, aplasia, pure, *1976:* Sept., **945–958**
structure and function, hemolytic anemias and, *1976:* Sept., 913–932
Erythrocytosis, inappropriate erythropoietin section and, *1975:* March, 437
Erythrogenesis imperfecta, *1976:* Sept., **945–958**
Erythropoiesis, copper and, *1976:* July, 687
inhibition in infection, *1976:* July, 837
thyroid hormones and, *1975:* Sept., 1133–1135
Escape beat, subjunctional, sequellae, *1976:* Jan., 12–15
Escape system, *1976:* Jan., 7
Esophagogastric varices, bleeding, portal hypertension and, *1975:* July, 947–949
Esophagus, carcinoma of, chemotherapy for, *1975:* March, 399–400
disorders, in aged, *1976:* Nov., 1141–1144
lower sphincter, biofeedback control, *1977:* July, 908
motility disorders, *1977:* March, 292
Essential hypertension, *1977:* May, 499, 612
Estradiol-17β, in hyperthyroid men, *1975:* Sept., 1110–1114
Estrogen(s), in hyperthyroid men, *1975:* Sept., 1110–1114
in hyperthyroid women, *1975:* Sept., 1119–1120
in pregnancy, *1977:* Jan., 49
pubertal changes, *1975:* Nov., 1295–1297

Estrogen(s) (*Continued*)
therapy, in metastatic breast cancer, *1975:* March, 427–428
trace metal concentrations and, *1976:* July, 789–791
Ethacrynic acid, and renal fatty acid utilization, *1975:* May, 704, 708
Ethambutol, in tuberculosis, *1977:* Nov., 1193–1194, 1199
Ethanol, liver injury from, *1975:* July, 899
metabolism of, *1975:* July, 909–910
Ethchlorvynol (Placidyl), *1977:* Nov., 1326
Ethics, of personal medical care, *1977:* July, 867–877
Ethionamide, *1977:* Nov., 1199, 1200
hepatoxicity of, *1975:* July, 905
Ethosuximide (Zarontin), *1975:* Nov., 1468
Excitation, re-entrant, *1976:* Jan., 23–44
Exercise, chronic airflow obstruction and, *1977:* Nov., 1225
for rheumatic disease, *1976:* Nov., 1187
in pregnancy, *1977:* Jan., 25
stress testing, *1976:* March, **313–324**
Exophthalmos, in Graves' disease, *1975:* Sept., 1179–1182, 1184
Extracorporeal circulation, liver dysfunction after, *1975:* July, 825
platelet transfusion with, *1977:* Sept., 1136
Extractable nuclear antigens (ENA), *1977:* March, 381
Extrapyramidal system, aging and, *1976:* Nov., 1315–1324
Extremities, lower, arteriosclerosis obliterans of, *1976:* Nov., 1080–1086
Eye problems, in Sjögren's syndrome, *1977:* March, 271–274

FALLING disease, *1976:* July, 691
Familial panhypopituitarism, *1975:* Sept., 1265
Familial polyposis, carcinoma and, *1975:* March, 347
Fanconi's anemia, *1975:* Nov., 1484–1485
Fat embolism, post-traumatic, roentgen signs, *1975:* Jan., 50–52, 54
Fatty acids, hepatic encephalopathy and, *1975:* July, 938
renal metabolism of, *1975:* May, 511–515
sodium and water conservation and, *1975:* May, 525–529
renal utilization of, *1975:* May, **699–711**
Fatty liver, after intestinal bypass, *1975:* July, 827
alcoholic, *1975:* July, 913
Felty's syndrome, *1977:* March, 223
Fenoprofen calcium, *1977:* March, 409
Fertility, Crohn's disease and, *1977:* Jan., 135
hypothyroidism and, *1975:* Sept., 1091–1094
Fetus, maternal drug ingestion and, *1977:* Jan., 188
maternal hypothyroidism and, *1977:* Jan., 69–74
Fetus (*Continued*)
thyroid function in, *1975:* Sept., **1099–1107**
Fever, in acute leukemia, *1976:* Sept., 993
Fibrinolytic system disorders, *1977:* Jan., 182
Fibroma, hepatic, *1975:* July, 1004
Fibromuscular disease, of renal arteries, *1977:* May, **623–641**
Filtration leukapheresis, in granulocyte collection, *1977:* Sept., 1122
Finger clubbing, cyanosis and cirrhosis and, *1975:* July, **983–987**
Fistula(s), in dialysis, psychological aspects, *1977:* July, 763
Flail chest, *1975:* Jan., 58
Fleischner lines, *1975:* Jan., 6, 9
Fluids and electrolytes, imbalance, in carcinoma, *1975:* March, **449–457**
Fluorescein angiography, retinal, *1977:* May, 562
5-Fluorouracil, in breast cancer, *1977:* Sept., 957–961
in colorectal cancer, *1977:* Sept., 991–993
in pancreatic cancer, *1977:* Sept., 995
in stomach cancer, *1977:* Sept., 995–997
Fluphenazine (Prolixin), *1977:* July, 898
Flurbiprofen, *1977:* March, 359
Folate, deficiency, *1975:* Nov., 1483
in hypothyroidism, *1975:* Sept., 1138
requirements, in pregnancy, *1977:* Jan., 8–10
Folic acid deficiency, *1977:* Jan., 169
Foot care, in peripheral arterial disease, *1976:* Nov., 1084
Fracture(s), spontaneous, copper deficiency and, *1976:* July, 691
Freund's complete adjuvant, *1976:* May, 474
Ftorafur, *1977:* Sept., 993
Fungal arthritis, *1977:* March, 322
Fungal infection, in granulocytopenic patient, *1977:* Sept., 1114–1115
of lung, *1977:* Nov., 1175–1179
Furadantin. See *Nitrofurantoin.*

GALLBLADDER, enlargement, *1975:* Jan., 124
ultrasound examination, *1975:* Jan., 128
Gallstones, *1975:* Jan., 123
cholesterol, *1975:* July, **1025–1033**
in sickle cell disease, *1976:* Sept., 936
Gallstone ileus, *1976:* Nov., 1153
Gamma globulin, for immunization against infectious hepatitis, *1975:* July, 858
Gamma-glutamyl cycle, glutathione and, *1975:* May, **649–666**
Gammopathy, monoclonal, benign essential, *1975:* March, 384–385
Ganglionic blocking drugs, *1977:* May, 681
Gangliosidosis, *1975:* July, 921
Gardner syndrome, *1975:* Sept., 1270
Gastric. See also *Stomach.*
Gastric cancer, *1977:* Sept., 995–997
Gastric ulcer, *1976:* Nov., 1166–1168
Gastroenteritis, cadmium and, *1976:* July, 760

Gastrointestinal disorders, biofeedback in, *1977:* July, **907–912**
in aged, *1976:* Nov., 1141–1157
Gastrointestinal system, thyroid function and, *1975:* Sept., 1127
Gastrointestinal tract, cancer of, *1977:* Sept., **991–999**
chemotherapy, *1975:* March, 399–402
disorders, in pregnancy, *1977:* Jan., **133–138**
hemorrhage, liver failure and, *1975:* July, 930
radiology, in liver disease, *1975:* July, 1021
Gaucher's disease, *1975:* July, 921
Genetic disorders, of thyroid, *1975:* Sept., **1263–1274**
Genetic factors, in chronic granulocytic leukemia, *1976:* Sept., 1003
in hypertension, *1977:* May, 478, 490, 532
in immunoregulation, *1977:* March, 206
Genital infection, in pregnancy, *1977:* Jan., **139–151**
Genitourinary tract carcinoma, chemotherapy in, *1975:* March, 406–407
Gentamicin, in granulocytopenic patient, *1977:* Sept., 1105–1109
Geriatric medicine (symposium), *1976:* Nov., **1059–1332**
preventive, *1976:* Nov., **1325–1332**
Geriatric patient, *1977:* July, **855–866**
Gestational diabetes, *1977:* Jan., 51
Giant cell arteritis, *1977:* March, **261–270**
Gilbert's syndrome, *1975:* July, 810–812
Glanzmann's thrombasthenia, platelet aggregation studies in, *1976:* Sept., 885–889, 896
Glioblastoma multiforme, *1977:* Sept., 1045–1047
Glioma, malignant, *1977:* Sept., 1045, 1048–1050
Glomerular filtration, renal metabolism and, *1975:* May, 507
Glomerulonephritis, *1977:* May, 614, 617
Glossitis, in alcoholic liver disease, *1975:* July, 913
Glucocorticoids, in renal ammonia production, *1975:* May, 639–642
Gluconeogenesis, renal, acid-base changes and, *1975:* May, 786–788
aminoacid metabolism and, *1975:* May, **751–761**
ammoniagenesis and, *1975:* May, 788–791
Glucose, homeostasis, *1977:* Jan., 44
renal carbon dioxide production and, *1975:* May, 544–546
renal metabolism of, *1975:* May, 515–516
sodium and water conservation and, *1975:* May, 532–535
renal uptake, *1975:* May, 618–621
Glucose-6-phosphate dehydrogenase, in hyperthyroidism, *1975:* Sept., 1135
Glucuronyl transferase deficiency, *1975:* July, 808–809
Glue sniffing, *1975:* Nov., 1450
Glutamate, renal conversion of glutamine to, *1975:* May, 558–560
Glutamate dehydrogenase, in renal ammoniagenesis, *1975:* May, 596–596
Glutaminase, gamma-glutamyl cycle and, *1975:* May, 657–659
in renal ammoniagenesis, *1975:* May, 584–589, 597–598, 629–631, 633–636
in renal glutamine deamination, *1975:* May, 670–672
in renal mitochondrial glutamine transport, *1975:* May, 560–562
Glutaminate, renal ammonia excretion and, *1975:* May, 673–675
Glutamine, gamma-glutamyl cycle and, *1975:* May, 657–659
in renal ammonia production, *1975:* May, 633–636
renal deamination, *1975:* May, **667–680**
renal metabolism of, *1975:* May, 511, 519–521
renal transport, *1975:* May, 675–678
mitochondrial, *1975:* May, **555–567**
renal uptake, *1975:* May, 782
Glutamine synthetase, *1975:* May, 584–589
Glutathione, renal function, *1975:* May, 649–666
Glutethimide, abuse, *1975:* Nov., 1449
Glycogen storage disease, *1975:* July, 921; *1977:* March, 300, 301
Glycoprotein, *1977:* March, 212
Goiter, adenomatous, surgery for, *1975:* Sept., 1258
in pregnancy, *1975:* Sept., 1090–1091
iodide-induced, *1975:* Sept., 1079–1083
multinodular, *1975:* Sept., 1228–1229
nontoxic, *1975:* Sept., **1221–1232**
of Plummer's disease, *1975:* Sept., 1204–1214
Goitrous cretinism, *1977:* Jan., 73
Gold, *1977:* March, 412–414
dysgenesis, thyroid dysfunction with, *1975:* Sept., 1271
pubertal changes, *1975:* Nov., 1294–1295
pulmonary fibrosis and, *1977:* Nov., 1364
Gonadotropins, *1975:* Nov., 1290–1294
in hyperthyroidism, *1975:* Sept., **1109–1121**
Gonadotropin-producing tumors, *1975:* March, 435
Gonococcal arthritis, *1977:* March, 320–322
Gonorrhea, in adolescents, *1975:* Nov., 1396–1398
Gout, *1976:* Nov., 1180; *1977:* March, **299–312**
roentgen features, *1977:* March, 391, 396
Granulocyte transfusions, in acute leukemia, *1975:* March, 369
infection and, *1977:* Sept., 1112
principles of, *1977:* Sept., **1119–1131**
Granulocytopenia, infection and, *1977:* Sept., **1101–1118**
Granuloma(s), in rheumatoid arthritis, *1977:* March, 218–220
Graves's disease, *1975:* Sept., 1167, 1170, **1177–1192**, 1268–1269; *1977:* Jan., 78
iodide-sensitivity after, *1975:* Sept., 1082

Graves's disease (*Continued*)
thyroidectomy in, *1975:* Sept., 1249, 1251
Growth and development, adolescent, *1977:* July, 840–844
delayed, *1975:* Nov., **1337–1347**
pubertal, *1975:* Nov., **1305–1317**
Growth hormone, levels of body trace metals and, *1976:* July, 787–788
Growth kinetics of solid tumors, *1975:* March, **339–346**
Guanethidine, *1977:* March, 292; May, 682–684
in adolescents, *1975:* Nov., 1381
in hyperthyroidism, *1975:* Sept., 1195
Gut cleansing, for hepatic encephalopathy, *1975:* July, 941
Gynecomastia, in hyperthyroidism, *1975:* Sept., 1109–1110

HAIR, kinky, Menkes syndrome, *1976:* July, 656, 659, 688, 700–701, 710
Haloperidol (Haldol), *1977:* July, 898
Halothane, hepatotoxicity of, *1975:* July, 902, 927
Hamartoma, *1977:* Sept., 1062
mesenchymal, *1975:* July, 1011
renal, fetal, *1977:* Sept., 1068
Hampton's hump, *1975:* Jan., 10
Hand-foot syndrome, *1976:* Sept., 934
Harris model, *1976:* Jan., 49
Hashimoto's thyroiditis, *1975:* Sept., 1166–1171, 1229–1230, 1259, 1267–1268
iodide myxedema with, *1975:* Sept., 1080–1082
Head, carcinoma of, *1975:* March, 405–406, 413–417
chemoimmunotherapy for, *1976:* May, 449
Headache, *1977:* July, 733
hypertension and, *1977:* May, 577
migraine, biofeedback for, *1977:* July, 919
relaxation response in, *1977:* July, 935
Heart. See also *Cardiac.*
arrhythmias. See *Arrhythmia(s).*
block, *1976:* Jan., 175–191. See also specific types, as *Bundle branch block.*
complete, hemodynamic changes, *1976:* Jan., 77
in myocardial infarction, *1976:* March, 241
infranodal, *1976:* Jan., **175–192**
congenital anomalies, pulmonary vasculature and, *1977:* Nov., 1281
cycle length, irregularity of, *1976:* Jan., 72
disease, hypertension and, *1977:* May, 523–527, **581–591**
in elderly, *1976:* Nov., **1059–1078**
in pregnancy, *1977:* Jan., **17–41**
ischemic, Holter diagnosis of, *1976:* March, 307
rheumatoid arthritis and, *1977:* March, 225
Heart (*Continued*)
disease, sudden death from, prevention of, *1976:* March, **245–282**
dysrhythmias (symposium), *1976:* Jan., **3–207**; March, **211–384.** See also *Arrhythmias;* and specific disorders.
electrophysiology of, *1976:* March, 213–217
failure, congestive, perfusion lung scan in, *1975:* Jan., 16
copper deficiency and, *1976:* July, 691
in aged, *1976:* Nov., 1062
hemodynamic changes during arrhythmias, *1976:* Jan., **69–80**
in hyperthyroidism, *1975:* Sept., 1194–1195
in scleroderma, *1977:* March, 288
infarct. See *Myocardial infarction.*
murmurs, in pregnancy, *1977:* Jan., 25
myocardial infarction, psychological aspects, *1977:* July, **711–721**
output, in borderline hypertension, *1977:* May, 498
rate, arrhythmias and, *1976:* Jan., 69–70
stroke volume, changes in, *1976:* Jan., 69–70
surgery, iatrogenic complications, *1975:* Jan., 86–88
thyroid function and, *1975:* Sept., 1125–1126
valves, injuries, *1975:* Jan., 78
prosthetic, in pregnancy, *1977:* Jan., 37–39
anticoagulants and, *1976:* Sept., 865
valvular disease, in aged, *1976:* Nov., 1068–1070
Heartburn, *1977:* Jan., 134
Heat stroke, *1976:* Nov., **1289–1296**
Heavy chain disease, in multiple myeloma, *1975:* March, 383–384
Height, growth, *1975:* Nov., 1307–1308
Hemangioendothelioma, infantile, *1975:* July, 1008
Hemangioma, cavernous, of liver, *1975:* July, 1007–1008
Hemansky-Pudlach syndrome, platelet aggregation in, *1976:* Sept., 890
Hematologic crises, in sickle cell disease, *1976:* Sept., 935
Hematologic diseases. See also specific disorders.
in pregnancy, *1977:* Jan., **165–199**
malignant, implications for therapy of solid tumors, *1977:* Sept., **945–951**
in aged, *1976:* Nov., **1253–1271**
Hematology, advances (symposium), *1976:* Sept., **853–1052**
Hematuria, radiologic evaluation, *1975:* Jan., **201–232**
Hemodialysis, in fulminant hepatic failure, *1975:* July, 934
psychological aspects of, *1977:* July, **759–769**
Hemoglobinopathy(ies), *1976:* Sept., 926–927
in adolescents, *1975:* Nov., 1487
in pregnancy, *1977:* Jan., 170–175

Hemolytic anemia, *1976:* Sept., **913–932**
in adolescents, *1975:* Nov., 1485–1487
Hemoperfusion, extracorporeal, in fulminant hepatic failure, *1975:* July, 933
Hemophilus influenzae pneumonia, *1977:* Nov., 1171, 1174
Hemorrhage, defibrination and, *1976:* Sept., 872
gastrointestinal, in aged, *1976:* Nov., 1148
liver failure and, *1975:* July, 930
intracerebral, hypertensive, *1977:* May, 567, 574–577
peptic ulcer and, *1976:* Nov., 1162
postsurgical, *1976:* Sept., 903
retinal, in hypertension, *1977:* May, 553, 560
variceal, portal hypertension and, *1975:* July, 947–949
Hemostasis, *1976:* Sept., 855–857
disorders of, *1976:* Nov., **1273–1287**
platelet aggregation studies in, *1976:* Sept., **881–911**
Hemothorax, *1975:* Jan., 74
Henderson-Hasselbalch equation, *1977:* Nov., 1382
Heparin, *1976:* Sept., 857–859
in defibrination syndrome, *1976:* Sept., **871–880**
Hepatic. See also *Liver.*
Hepatic disease, in pregnancy, *1977:* Jan., **129–133**
Hepatic encephalopathy, chronic, *1975:* July, **937–944**
Hepatic failure, fulminant, *1975:* July, **927–935**
Hepatic storage disease, *1975:* July, 815
Hepatitis, alcoholic, *1975:* July, 910, 912–913
renal failure and, *1975:* July, 959–960
autoimmunity in, *1975:* July, **869–876**
chronic, *1975:* July, **863–867**
extrahepatic manifestations, *1975:* July, 872–874
drug-induced, *1975:* July, 871
in adolescents, *1975:* Nov., **1453–1460**
in drug abusers, *1975:* July, **843–848**
isoniazid-associated, *1977:* Nov., 1189
neonatal, *1975:* July, 924
viral, *1977:* March, 324
active and passive immunization, *1975:* July, **857–862**
cholestasis in, *1975:* July, 818
fulminant hepatic failure after, *1975:* July, 927
postoperative, *1975:* July, 825
type A, *1975:* July, **831–834**
type B, antigens and antibodies, *1975:* July, **849–855**
epidemiology, *1975:* July, **835–842**
immune serum globulin and, *1975:* July, 861
in drug abuser, *1975:* July, **843–848**
Hepatocellular carcinoma, *1975:* July, 990
Hepatocellular disease, postoperative, *1975:* July, 825–828
Hepatocellular necrosis, metabolic disorders and, *1975:* July, 920, 924–925
Hepatocellular tumors, benign, *1975:* July, 996–1002
Hepatocirculatory failure, *1975:* July, **955–962**
Hepatoma, *1975:* July, **989–994**
chemotherapy for, *1975:* March, 420–421
hypoglycemia in, *1975:* March, 436
in alcoholics, *1975:* July, 911
Hepatomegaly, metabolic disorders and *1975:* July, 920
roentgen evaluation, *1975:* Jan., **145–167**
Hepatorenal syndrome, *1975:* July, 955
Hepatotoxins, *1975:* July, 899
Hereditary spherocytosis, *1976:* Sept., 922–924
Heredity, blood pressure and, *1977:* May, 478, 490, 532
Hernia, hiatus, esophageal symptoms and, *1976:* Nov., 1143
Heroin, abuse, medical complications, *1975:* Nov., 1446
pulmonary edema from, *1977:* Nov., 1324
Herpes infection, genital, *1975:* Nov., 1401
Herpes simplex virus type II, *1977:* Jan., 143
Heterotopias, of liver, *1975:* July, 1011
Hiatus hernia, esophageal symptoms and, *1976:* Nov., 1143
Hidradenitis suppurativa, *1975:* Nov., 1476
His premature beat, *1976:* Jan., 37, 169, 171
His-Purkinje system, concealment within, *1976:* Jan., 161–172
Histocompatibility, genetics of, *1977:* March 335
Histocompatibility complex, *1977:* March, **331–345**
Histocompatibility testing, for granulocyte transfusion, *1977:* Sept., 1126–1127
Histoplasmosis, *1977:* Nov., 1175–1176
Hodgkin's disease, *1975:* March, 387–397; *1976:* Nov., 1236
immunodeficiency in, *1976:* May, 629
immunotherapy for, chemotherapy with, *1976:* May, 450–451
staging, *1976:* Sept., 1044
Holter monitoring, *1976:* March, **299–313**
Hormonal changes, of adolescence, *1975:* Nov., **1289–1304**
Hormone(s). See also specific hormones.
ectopic, lung cancer and, *1977:* Nov., 1207
in metastatic breast cancer, *1977:* Sept., 967–969
sex. See *Androgen; Estrogen.*
jaundice in pregnancy and, *1977:* Jan., 130
thyrcid. See *Thyroid hormones* and specific hormones.
trace metal interactions with, *1976:* July, **779–797**
tumors producing, *1975:* March, **431–440**
Horner's syndrome, *1977:* Sept., 1054
Hospitalization, of adolescent, *1975:* Nov., 1284–1286
Host, defense, in aged, *1976:* Nov., **1225–1240**

Host (*Continued*)
defense, in cancer, *1975:* March, 327
in leukemia, *1976:* Sept., 1020–1026
idiosyncrasy, liver injury and, *1975:* July, 901
immunosuppressed, infection in, *1975:* March, **494–501**
Human leukocyte antigen (HLA), *1977:* March, 332, 341, 347
B27, in Reiter's syndrome, *1977:* March, 365, 371
Human placental lactogen (HPL), *1977:* Jan., 49
Humidifier lung, *1977:* Nov., 1257
Humoral factors, in compensatory renal growth, *1975:* May, **771–780**
Hutchinson's melanotic freckle, *1977:* Sept., 1014
Hydatidiform mole, *1977:* Jan., 82
Hydralazine, *1977:* May, 688
pulmonary toxicity, *1977:* Nov., 1364
Hydrocephalus, normal pressure, *1976:* Nov., 1307
Hydrochlorothiazide, inhibition by probenecid, *1975:* May, 741–743
Hydrothorax, traumatic, roentgen signs, *1975:* Jan., 41–42, 46
Hydroxychloroquine, *1977:* March, 238, 411
Hyperammonemia, in liver failure, *1975:* July, 929
Hyperbilirubinemia, conjugated, *1975:* July, 812–816
unconjugated, *1975:* July, 807–812
Hypercalcemia, in malignant disease, *1975:* March, **441–447**
lung cancer and, *1977:* Nov., 1207
Hypercholesterolemia, sudden coronary death and, *1976:* March, 254–259
Hyperiodothyroninemia, neonatal, transient, *1975:* Sept., 1103
Hyperlipoproteinemia(s), *1975:* July, 921
diabetes and, *1975:* Nov., 1354
in adolescents, *1975:* Nov., **1359–1369**
Hypernephroma, *1975:* March, 293
hypercalcemia with, *1975:* March, 441
serotherapy in, *1976:* May, 614
Hyperparathyroidism, *1976:* Nov., 1217
lung cancer and, *1977:* Nov., 1207
Hypersensitivity, cellular, vasculitis from, *1977:* March, 255
Hypersensitivity pneumonitis, *1977:* Nov., 1257
Hypersensitivity reactions, delayed,
levamisole and, *1976:* May, 524
local immunotherapy, *1976:* May, 389–411
transfer factor and, *1976:* May, **585–590**
Hypertension (symposium), *1977:* May, **463–701**
borderline, *1977:* May, **495–511**
cadmium and, *1976:* July, 759, 764–766
classical, *1977:* May, 513
epidemiology of, *1977:* May, **467–486**
essential, biofeedback training for, *1977:* July, 919
Hypertension (symposium) (*Continued*)
essential, prostaglandins and, *1975:* May, 720–723
genetic factors in, *1977:* May, 478, 490, 532
heart disease with, *1977:* May, **581–591**
in adolescents, *1975:* Nov., **1371–1383**
in children, *1977:* May, **487–493**
in coarctation of aorta, *1977:* May, **655–673**
in elderly, *1977:* Mary, **513–529**
medical management, *1977:* May, **675–698**
neurologic complications, *1977:* May, **565–580**
optic fundus in, *1977:* May, **547–564**
portal, *1975:* July, **945–953**
renal hypoperfusion and, *1975:* July, 958
prevention of, *1977:* May, 483–484
pulmonary, *1977:* Nov., 1280–1285. 1290–1304
drug-induced, *1977:* Nov., 1361–1362
relaxation training in, *1977:* July, 932–934
renal, in pregnancy, *1977:* Jan., 104
renal and adrenal, abdominal radiography in, *1975:* Jan., **169–200**
renal disease and, *1977:* May, **611–622**
risk factors, in, *1977:* May, 477–483, 516–519
spontaneous, experimental, *1977:* May, **593–609**
sudden coronary death and, *1976:* March, 254–259
systolic, *1977:* May, 513, 521–527
work environment and, *1977:* May, **531–545**
Hypertensive emergencies, *1977:* May, 691, 694
Hyperthyroidism, anemia in, *1975:* Sept., 1139–1141
cardiovascular system in, *1975:* Sept., **1193–1201**
catecholamines in, *1975:* Sept., 1124
ectopic thyrotropin-producing tumors and, *1975:* March, 437
gonadal steroids and gonadotropins in, *1975:* Sept., **1109–1121**
in pregnancy, *1975:* Sept., 1094–1097; *1977:* Jan., 77–83
iodide-induced, *1975:* Sept., 1083–1085
neuromuscular function in, *1975:* Sept., 1072
of Graves' disease, *1975:* Sept., 1178–1179, 1183, 1185, 1187–1188
of Plummer's disease, *1975:* Sept., **1203–1215**
serum triiodothyronine in, *1975:* Sept., 1066
surgery for, *1975:* Sept., 1248–1251
TRH testing in, *1975:* Sept., 1051
Hyperuricemia, *1977:* March, **299–312**
Hyperviscosity syndrome, *1977:* March, 221
Hypogeusia, zinc and, *1976:* July, 679
Hypoglycemia, extrapancreatic tumors and, *1975:* March, 435

Hypoglycemia (*Continued*)
fulminant hepatic failure and, *1975:* July, 928
Hypoglycemic agents, in elderly, *1976:* Nov., 1200–1206
Hypogonadal dwarfism, zinc deficiency and, *1976:* July, 676–677, 785
Hypogonadism, hypogonadotropic, *1975:* Nov., 1341–1342
Hyponatremia, in aged, *1976:* Nov., 1116
Hypophysectomy, in metastatic breast cancer, *1975:* March, 428–429
Hyposmia, zinc and, *1976:* July, 679
Hypothalamic disease, TRH testing in, *1975:* Sept., 1050
Hypothalamic-pituitary defects, hypothyroidism with, *1975:* Sept., 1265
Hypothalamic-pituitary-thyroid axis, *1975:* Sept., **1045–1053**
Hypothalamus, function, *1975:* Nov., 1289–1290
Hypothermia, thyroid function and, *1975:* Sept., 1128
Hypothyroidism. See also *Myxedema.*
anemia in, *1975:* Sept., 1136–1139
catecholamines in, *1975:* Sept., 1124
delayed puberty and, *1975:* Nov., 1344
genetic causes, *1975:* Sept., 1264–1267
in aged, mental changes, *1976:* Nov., 1301
in pregnancy, *1975:* Sept., 1091–1094; *1977:* Jan., 69–74
iodide-induced, *1975:* Sept., 1079–1083
lipid abnormalities in, *1975:* Sept., 1072
neonatal, *1977:* Jan., 75–77
neonatal, screening for, *1975:* Sept., 1104–1105
thyroid hormone therapy in, *1975:* Sept., 1160
neuromuscular function in, *1975:* Sept., 1072
primary, *1975:* Sept., 1048–1049
thyroid hormone therapy in, *1975:* Sept., 1153
Hypoventilation, in cirrhosis, *1975:* July, 984
Hypoxemia, liver dysfunction with, *1975:* July, 826
Hypoxia, hypertensive pulmonary vascular disease with, *1977:* Nov., 1285–1290
Hysteria, *1977:* July, 732

IBUPROFEN, *1977:* March, 410
Identity, development in adolescence, *1977:* July, 844
Idioventricular rhythm, accelerated, *1976:* Jan., 16
Illness, concept of, *1977:* July, **703–710**
onset, life change and, *1977:* July, **825–838**
Imidazole carboxamide (DTIC) in chemoimmunotherapy of malignant melanoma, *1976:* May, 443–445
Imipramine (Tofranil), *1977:* July, 894
Immune challenge regimens, effects on skin neoplasms, *1976:* May, 394–395
Immune-complex, deposit, vasculitis from, *1977:* March, 249
in rheumatic diseases, *1977:* March, 385
Immune reactions, cell-mediated, clinical applications, *1976:* May, 389
therapeutic, induction of, *1976:* May, 391
Immune response, disorders of. See *Immunodeficiency disorders.*
in aged, *1976:* Nov., **1253–1271**
regulation of, *1977:* March, 206–207, 212
Immune response (Ir) genes, *1977:* March, 206
Immune RNA, in immunotherapy of cancer, *1976:* May, **567–583**
Immune system, autoimmune diseases and, *1977:* March, **205–215**
function, assessing, *1975:* March, 333–335
in liver disease, *1975:* July, 874
separated components, intralesional administration of, *1976:* May, 411–414
Immune thrombocytopenic purpura, platelet aggregation in, *1976:* Sept., 901–902
Immunity, liver-specific, *1975:* July, 874
Immunization, active and passive, against viral hepatitis, *1975:* July, **857–862**
anaphylactic reactions to, *1974:* Jan., 151
Immunodeficiency, evaluation of, *1976:* May, **623–639**
in leukemia, *1976:* Sept., 1020–1026
pneumonia with, *1977:* Nov., 1179–1180
in alcoholic liver disease, *1975:* July, 917
Immunodeficiency diseases, incidence of cancer with, *1976:* May, 624
thymosin in treatment of, *1976:* May, **591–606**
Immunohematologic disorders, in pregnancy, *1977:* Jan., 177
Immunologic memory, *1976:* May, 399
Immunologic vasculitis, *1977:* March, 248–256
Immunomodulators, in treatment of cancer, *1976:* May, **473–497, 511–537**
Immunosuppressive therapy, *1977:* Jan., 105
in rheumatic diseases, *1977:* March, **419–437**
Immunotherapy, chemotherapy with, in human solid tumors, *1976:* May, **441–462**
in idiopathic thrombocytopenic purpura, *1976:* Sept., **971–986**
in malignant disease, *1975:* March, 327–337; *1976:* May, **387–651**
immune RNA in, *1976:* May, **567–583**
thymosin in, *1976:* May, **591–606**
transfer factor in, *1976:* May, **585–590**
in malignant melanoma, *1977:* Sept., 1017–1019
in metastatic breast cancer, *1977:* Sept., 972–975
infection and, *1975:* March, **495–501**
local, for malignant and premalignant lesions, *1976:* May, **389–418**
of leukemia, *1976:* Sept., 996, **1019–1042**

Immunotherapy (*Continued*)
principles of, *1976:* Sept., 1026–1028
specific, with neuraminidase-modified leukemic cells, *1977:* Sept., **1083–1100**
Impotence, *1977:* July, 815
Imuran. See *Azathioprine.*
Incontinence, fecal, biofeedback control of, *1977:* July, 909
Inanedione anticoagulants, *1976:* Sept., 859–861
Independence, *1977:* July, 842
Inderal. See *Propranolol.*
Indomethacin, *1977:* March, 238, 307, 359, 407
Infant(s), liver disease in, metabolic disorders and, *1975:* July, **919–925**
newborn, ataxia of, manganese and, *1976:* July, 771
cholestatic syndromes in, *1975:* July, 819
goiter in, *1975:* Sept., 1079
hepatitis in, *1975:* July, 841
hyperbilirubinemia in, *1975:* July, 812
thyroid function in, *1975:* Sept., **1099–1107**
Infantile hemangioendothelioma, *1975:* July, 1008
Infarction, myocardial. See *Myocardial infarction.*
pulmonary, thromboembolic disease with, *1975:* Jan., 10–15
Infection, in fulminant hepatic failure, *1975:* July, 931
in granulocytopenic patient, *1977:* Sept., **1101–1118**
in leukemia, *1975:* March, 367–369; *1976:* Sept., 991–993
in multiple myeloma, *1975:* March, 379
in pregnancy, *1977:* Jan., 28
in rheumatoid patient, *1977:* March, 226
resistance to, levamisole, and, *1976:* May, 526
respiratory, in aged, *1976:* Nov., 1125
sickle cell anemia and, *1976:* Sept., 938
trace elements and, *1976:* July, **831–849**
Infectious arthritis, *1976:* Nov., 1181; *1977:* March, **313–329**
Infectious disease, in elderly, *1976:* Nov., 1224, **1225–1240**
Infectious endocarditis, *1976:* Nov., 1227–1229
Infectious hepatitis, passive immunization, *1975:* July, 858
Inflammatory bowel disease, delayed puberty and, *1975:* Nov., 1344
in pregnancy, *1977:* Jan., 135
Informed consent, *1977:* July, 871
Influenza, pneumonia after, *1977:* Nov., 1173–1175
pregnancy and, *1977:* Jan., 116
Infranodal block, *1976:* Jan., **175–192**
Infusion chemotherapy, regional arterial, *1975:* March, **411–424**
Insect infestations, *1975:* Nov., 1479
Insulin, and body fuel metabolism, in pregnancy, *1977:* Jan., 48
Insulin (*Continued*)
in aged, *1976:* Nov., 1201
in pregnant diabetic, *1977:* Jan., 57–59
trace metal interactions, *1976:* July, 792
International Registry of Tumor Immunotherapy, *1976:* May, **641–648**
Interviewing, of adolescents, *1975:* Nov., 1281–1282
Intestine(s).
bypass surgery, liver disease after, *1975:* July, 827
cancer of, chemoimmunotherapy for, *1976:* May, 446–448
inflammatory disease, delayed puberty and, *1975:* Nov., 1344
obstruction, *1976:* Nov., 1152
polyposis, carcinoma and, *1975:* March, 347
Intracerebral hemorrhage, hypertensive, *1977:* May, 567, 574–577
Intrauterine devices, for adolescents, *1975:* Nov., 1414–1416
Intravascular coagulation, disseminated, fibrinolysis and, *1976:* Sept., 874
Iodides, drug synergism, *1975:* Sept., 1082
effects on thyroid function, *1975:* Sept., **1075–1088**
in therapy of thyrotoxicosis, *1975:* Sept., 1085–1086
transport defect, *1975:* Sept., 1266
Iodine, protein-bound, determinations, *1975:* Sept., 1064
radioactive, therapy with, *1975:* Sept., **1217–1220**
renal clearance, *1975:* Sept., 1076
thyroidal uptake, evaluation of, *1975:* Sept., 1070–1071
Iodothyronine synthesis, disorders of, *1975:* Sept., 1266
Iridocyclitis, in rheumatoid disease, *1975:* Nov., 1499–1500
Iron, metabolism, infection and, *1976:* July, 831–838
requirements, in pregnancy, *1977:* Jan., 8–10
Iron deficiency anemia, in adolescents, *1975:* Nov., 1481–1483
in hyperthyroidism, *1975:* Sept., 1140
in hypothyroidism, *1975:* Sept., 1138
in pregnancy, *1977:* Jan., 168
Irradiation. See *Radiation; Roentgen.*
Irritable bowel syndrome, biofeedback in, *1977:* July, 911
Ischemic heart disease, *1977:* May, 587–589
in aged, *1976:* Nov., 1063–1068
Isoniazid, *1977:* Nov., 1193–1194, 1197, 1199
fulminant hepatic failure after, *1975:* July, 927
hepatotoxicity of, *1975:* July, 881, 904; *1976:* May, 504
prophylactic, *1977:* Nov., 1189
Isoproterenol, in acute myocardial infarction, *1976:* March, 237
Itai-itai, *1976:* July, 760

JAMES, nodal bypass tract of. *1976:* Jan., 25
Jaundice, cholestatic, *1975:* July, **817–821**
drug-induced, *1975:* July, **897–907**
halothane, *1975:* July, 902
in aged, *1976:* Nov., 1154
in pregnancy, *1977:* Jan., 130
nonhemolytic, congenital, *1975:* July, 808–809
obstructive, radiologic approach, *1975:* Jan., **121–143**
vs. drug-induced liver disease, *1975:* July, 898
postoperative, *1975:* July, **823–829**
Jodbasedow's disease, *1975:* Sept., 1084
Joint(s), aging, *1976:* Nov., 1174
disease, degenerative, *1976:* Nov., 1174–1177
infections, *1977:* March, **313–329**
inflammation. See specific disorders, as *Rheumatoid arthritis; Gout.*
Junctional parasystole, *1976:* Jan., 25
Junctional premature beats, *1976:* Jan., 37
Junctional rhythm, *1976:* Jan., 13–15

KAPOSI's hemorrhagic sarcoma, local immunotherapy for, *1976:* May, 409
Kayser-Fleischer rings, *1976:* July, 709
Kent conduction, *1976:* Jan., 42
Keratoconjunctivitis sicca, *1977:* March, 271
Keratosis, immunotherapy in, *1976:* May, 391
Ketoacidosis, *1977:* Jan., 58
α-Ketoglutarate, renal metabolism of, *1975:* May, 585, 589
renal uptake, *1975:* May, 523–524
Kidney(s). See also *Renal.*
adaptation to potassium-loading, *1975:* May, **763–769**
ammonia excretion, glutamine and, *1975:* May, **667–680**
ammoniagenesis. See *Ammonia, renal production.*
blood flow, *1975:* May, 539–544
renal metabolism and, *1975:* May, 507
carcinoma of, *1975:* March, **293–299**
circulation, cardiac arrhythmias and, *1976:* Jan., 75
clear-cell carcinoma of, serotherapy in, *1976:* May, 614
clearance of iodine, *1975:* Sept., 1076
cystic, roentgen signs, *1975:* Jan., 223–225, 228–229
disease, delayed puberty and, *1975:* Nov., 1342
hypertension and, *1977:* May, **611–622, 623–641, 643–653**
in aged, *1975:* Nov., **1105–1119**
in gout, *1977:* March, 305–306
in pregnancy, *1977:* Jan., 89–109
distribution and transport of substrates, *1975:* May, **539–554**
energy metabolism, thyroidal regulation, *1975:* May, **605–614**
excretion by non-ionic diffusion, *1975:* May, **681–698**
Kidney(s) (*Continued*)
failure, liver disease and, *1975:* July, **955–962**
fuels, *1975:* May, 516
function, in Sjögren's syndrome, *1977:* March, 277
glutamine mitochondrial transport, ammoniagenesis and, *1975:* May, **555–567**
growth, compensatory, humoral factors in, *1975:* May, **771–780**
in multiple myeloma, *1975:* March, 377
in scleroderma, *1977:* March, 288
in sickle cell disease, *1976:* Sept., 936
mitochondrial membrane transport systems, *1975:* May, 555–557
oxidative metabolism, *1975:* May, **507–522**
palmitic acid utilization, *1975:* May, **699–711**
prostaglandin concentration, *1975:* May, 723–728
sodium reabsorption, metabolic support for, *1975:* May, **523–538**
transplantation, hypertension and, *1977:* May, 615
transport of substrates, *1975:* May, **615–627**
trauma, hematuria with, *1975:* Jan., 207, 211–212, 213
tumors, Wilms', *1977:* Sept., 1061–1068
uric acid excretion, *1977:* March, 300
Klebsiella pneumonia, *1977:* Nov., 1168–1170
Klinefelter's syndrome, *1975:* Nov., 1341
Korotkoff sounds, in children, *1977:* May, 488

LABETALOL, *1977:* May, 620
Labile hypertension, *1977:* May, 495
Labor and delivery, cardiovascular problems and, *1977:* Jan., 29–31
hemodynamic alterations with, *1977:* Jan., 19–23
in diabetic, *1977:* Jan., 60
respiration and, *1977:* Jan., 115
Laboratory testing, in rheumatic diseases, *1977:* March, 377–387
Lactate, renal carbon dioxide production and, *1975:* May, 547–550
renal metabolism of, *1975:* May, 511–512, 521
sodium and water conservation and, *1975:* May, 529–532
renal production, *1975:* May, 548
renal uptake, *1975:* May, 621–624
Lactation, *1977:* Jan., **153–163**
Lactulose, for hepatic encephalopathy, *1975:* July, 942
Lacunar infarction, *1977:* May, 567, 571–573
LAF (Lymphocyte-activating factor), *1976:* May, 479
Large cell anaplastic carcinoma, of lung, *1977:* Sept., 985
Lead, drug metabolism and, *1976:* July, 825–827

Lead (*Continued*)
effect on endocrine function, *1976:* July, 781
Lecithin:cholesterol acyltransferase deficiency, *1976:* Sept., 925
Left ventricular hypertrophy, *1977:* May, 582–583
Leg ulcers, in sickle cell disease, *1976:* Sept., 935
Leiomyoma, of liver, *1975:* July, 1006
Lentigo maligna melanoma, *1977:* Sept., 1014
Leukapheresis, filtration, in granulocyte collection, *1977:* Sept., 1122
in chronic granulocytic leukemia, *1976:* Sept., 1010
Leukemia, acute, in children, *1976:* Sept., **987–1000**
asparaginase in, *1976:* Sept., 966–968
granulocytic, chronic, *1976:* Sept., **1001–1018**
immunodeficiency, in, *1976:* May, 629–631
immunotherapy of, *1976:* May, 391, **463–472;** Sept., **1019–1042**
neuraminidase-modified cells in, *1976:* May, 539–549; *1977:* Sept., 1083–1100
in aged, *1976:* Nov., 1268
in children, implications for therapy of solid tumors, *1977:* Sept., **945–951**
infection, in granulocytopenic patients, *1977:* Sept., **1101–1118**
MER in, *1976:* May, 484–485
myelocytic, acute, neuraminidase-modified cells in therapy of, *1977:* Sept., 1084
myelogenous, acute, *1975:* March, **363–373**
chronic, as granulocyte donor, *1977:* Sept., 1119
platelet aggregation in, *1976:* Sept., 899
serotherapy in, *1976:* May, 612–613
Leukemic cells, neuraminidase-modified, in immunotherapy, *1977:* Sept., **1083–1100**
Leukoagglutinin reaction, *1977:* Nov., 1332
Leukoagglutinins, *1977:* March, 332
Leukocyte(s), polymorphonuclear, zinc and, *1976:* July, 803
Leukocyte alkaline phosphatase (LAP), in chronic granulocytic leukemia, *1976:* Sept., 1005
Leukocyte endogenous mediator, trace metal metabolism and, *1976:* July, 842–844
zinc and, *1976:* July, 680
Leukopenia, splenomegaly with, *1977:* March, 223
Levamisole, *1977:* March, 416
as immunomodulator in cancer, *1976:* May, **523–537**
in metastatic breast cancer, *1977:* Sept., 973–975
in squamous cell lung cancer, *1976:* May, 448–449
side-effects, *1976:* May, 529
Levothyroxine, *1975:* Sept., 1151
Librium. See *Chlordiazepoxide.*
Lidocaine, electrophysiologic aspects, *1976:* March, 219–220
for arrhythmias, *1976:* March, 224
in acute myocardial infarction, *1976:* March, 235, 237
Life change, onset of illness and, *1977:* July, **825–838**
Liothyronine, *1975:* Sept., 1151
Liotrix, *1975:* Sept., 1151
Lipid(s), abnormalities, thyroid dysfunction and, *1975:* Sept., 1072
plasma, thyroid function and, *1975:* Sept., 1127
Lipoid pneumonia, *1976:* Nov., 1134
Lithium, in manic-depressive disorders, *1977:* July, 897–898
Liver. See also *Hepatic.*
abscess, *1975:* March, 268, 269
bilirubin metabolism and clearance, *1975:* July, 805–806
biopsy, *1975:* July, 1022–1023
carcinoma of, chemotherapy for, *1975:* March, 417–420
drug-induced, *1975:* July, 883
primary, *1975:* July, **989–994**
circulatory failure, *1975:* July, **955–962**
cirrhosis of. See *Cirrhosis.*
degeneration, selenium and, *1976:* July, 745–746
disease. See also *Hepatitis.*
alcoholic, *1975:* July, **909–918**
cholestasis in, *1975:* July, 818–821
diagnostic methods in, *1975:* July, **1015–1023**
drug-induced, *1975:* July, **897–907**
hemolysis of, *1976:* Sept., 924–925
in pregnancy, *1977:* Jan., **129–133**
organ-specific immunity in, *1975:* July, 874
parenchymal, drug-metabolism in, *1975:* July, **887–896**
portal hypertension in, *1975:* July, **945–953**
drug reactions, *1975:* July, **877–885**
dysfunction, after BCG therapy for cancer, *1976:* May, 503–504
after surgery, *1975:* July, **823–829**
constitutional, *1975:* July, 810–812
enlargement, roentgen evaluation, *1975:* Jan., **145–167**
failure, fulminant, *1975:* July, **927–935**
fibrosis, alcoholic, *1975:* July, 911
function, in therapy of leukemia, *1976:* Sept., 990
inflammation. See *Hepatitis.*
metabolic defects and, *1975:* July, **919–925**
nodular hyperplasia, *1975:* July, 996–999
radioisotopic examination, *1975:* Jan., 126–127
radionuclide scanning, *1975:* Jan., 157–159
scanning, for metastases, *1975:* March, **247–276**
transplantation, *1975:* July, 828
tumors, benign, *1975:* July, **995–1013**

Liver (*Continued*)
ultrasonic scanning, *1975:* Jan., 130–131, 164
vascular studies, *1975:* Jan., 150–152
Liver cell adenoma, *1975:* July, 1000–1002
Lown-Genong-Levine syndrome, *1976:* Jan., 22, 43, 102
Loxapine. See *Dibenzoxazepine.*
Loxitane. See *Dibenzoxazepine.*
Lucofen SA. See *Chlorphentermine.*
Lung(s). See also *Pulmonary.*
biopsy, *1975:* March, 280–281
carcinoma of, *1976:* Nov., 1245; *1977:* Sept., **979–989;** Nov., 1205–1218
chemotherapy for, *1975:* March, 403–404
disseminated, chemoimmunotherapy for, *1976:* May, 448–449
in women, *1975:* March, **315–325**
radiology of, *1975:* Jan., **95–120**
changes with aging, *1976:* Nov., 1121
contusion, *1975:* Jan., 46
diseases (symposium on), *1977:* Nov., **1161–1408**
diffuse, *1977:* Nov., 1264
in pregnancy, *1977:* Jan., **111–128**
infiltrative, *1977:* Nov., **1251–1266**
obstructive. See also *Bronchitis; Emphysema.*
oxygen therapy in, *1977:* Nov., 1397–1408
vascular, *1977:* Nov., **1279–1307**
edema, cadmium and, *1976:* July, 760
granulomas of, *1977:* March, 219
herniation, *1975:* Jan., 49, 51
infection, *1977:* Nov., 1163–1183. See also *Pneumonias,* and specific causes.
fungal, *1977:* Nov., 1175–1179
in Sjögren's syndrome, *1977:* March, 277
sickle cell disease and, *1976:* Sept., 938
laceration and hematoma, *1976:* Jan., 46, 47
lymphangitic carcinomatosis of, *1977:* Nov., 1261
metastases, *1975:* March, **277–283**
necrosis, from pneumonia, *1977:* Nov., 1168
percutaneous needle biopsy, *1975:* Jan., 112–113
re-expansion, pulmonary edema after, *1977:* Nov., 1331
scan, perfusion, in thromboembolic disease, *1975:* Jan., 16–26
thromboembolic disease, *1976:* Sept., 861–863
Lupoid hepatitis, *1975:* July, 869
Lupus erythematosus, systemic, *1977:* March, **229–240**
antibodies in, *1977:* March, 211
drug-induced, *1977:* Nov., 1364
immunosuppressive therapy in, *1977:* March, 427–430
in adolescents, *1975:* Nov., 1497–1505
vasculitis of, *1977:* March, 249
Lupus erythematosus cell preparation, *1977:* March, 380
Lupus erythematosus cells, hepatitis and, *1975:* July, 870
Luteinizing hormone, in hyperthyroid women, *1975:* Sept., 1119–1120
Lymph node dissection, prophylactic, in malignant melanoma, *1977:* Sept., 1016
Lymphangiography, in staging of ovarian cancer, *1977:* Sept., 1004
Lymphangioma, of liver, *1975:* July, 1010
Lymphangiosarcoma, local immunotherapy for, *1976:* May, 409–411
Lymphangitic carcinomatosis of lung, *1977:* Nov., 1261
Lymphocyte(s), effect of zinc on, *1976:* July, 799
Lymphocyte-activating factor (LAF), *1976:* May, 479
Lymphocyte stimulation, levamisole-induded, *1976:* May, 525
Lymphokine preparations, intratumoral administration of, *1976:* May, 411–412
Lymphoma(s), Burkitt's, *1977:* Sept., **1073–1082**
chemoimmunotherapy for, *1976:* May, 450–451
immunodeficiency in, *1976:* Sept., 1020–1026
in aged, *1976:* Nov., 1260
in pregnancy, *1977:* Jan., 166
management, *1975:* March, **387–397**
non-Hodgkin's, chemotherapy of, *1976:* Sept., **1043–1052**
serotherapy of, *1976:* May, 612–614
Lymphomatous disorders, in Sjögren's syndrome, *1977:* March, 278
Lymphosarcoma, *1976:* Sept., 1044
Lysyl oxidase, copper and, *1976:* July, 696

MACRODANTIN. SEE *Nitrofurantoin.*
Macrophages, effect of zinc on, *1976:* July, 803
Macular star, *1977:* May, 555
Mahaim tract, *1976:* Jan., 25, 37, 44
Majjocci's purpura, *1977:* March, 253
Malignant disease. See also *Carcinoma.*
anatomic extent of, *1977:* Sept., 947
combination chemotherapy for, *1977:* Sept., 949
immunodeficiency in, evaluation of patient, *1976:* May, **623–639**
immunotherapy in, symposium, *1976:* May, **387–651**
in aged, *1976:* Nov., **1241–1251**
prognostic factors, importance of, *1977:* Sept., 948
serotherapy of, *1976:* May, **607–622**
Malignant gliomas, *1977:* Sept., 1045, 1048–1050
Malignant melanoma, *1975:* March, 301–308; *1977:* Sept., **1013–1025**
chemoimmunotherapy for, *1976:* May, 443–445
chemotherapy for, *1975:* March, 404
disseminated, BCG as adjunct to surgery, *1976:* May, **431–439**
intralesional BCG for, *1976:* May, **419–430**

Malignant melanoma (*Continued*)
serotherapy in, *1976:* May, 615–617
Manganese, abnormalities, diagnosis of, *1976:* July, **655–660**
biochemistry of, *1976:* July, **713–727**
brain dopamine and, *1976:* July, **729–738**
deficiency, congenital anomalies and, *1976:* July, 771–773
endocrine function and, *1976:* July, 781, 782
Manic-depressive disorders, lithium in, *1977:* July, 897–898
Marfan's syndrome, *1977:* Jan., 36
Marihuana, *1975:* Nov., 1450
Mast cells, effect of zinc on, *1976:* July, 800
Masturbation, in dialysis patients, *1977:* July, 760
Mediastinal lipomatosis, steroid-induced, *1977:* Nov., 1356
Mediastinoscopy, *1975:* March, 280
Mediastinostomy, anterior, *1977:* Nov., 1209
Mediastinum, injuries to, roentgen signs, *1975:* Jan., 59
Medical care, ethics of, *1977:* July, **867–877**
Medullary carcinoma of thyroid, *1975:* March, 462–463; Sept., 1269
Melanoma, malignant, *1977:* Sept., **1013–1025.** See also *Malignant melanoma.*
Mellaril. See *Thioridazine.*
Mendelson's syndrome, *1977:* Nov., 1327
Meningitis, in aged, *1976:* Nov., 1229
Menkes kinky hair syndrome, *1976:* July, 656, 659, 688, 700–701, 710
Menstruation, disorders of, in adolescents, *1975:* Nov., **1385–1394**
Mental changes, organic, in cancer, *1977:* July, 743–744
Mental status assessment, in elderly, *1977:* July, 864
Meralluride, and renal fatty acid utilization, *1975:* May, 702, 704
6-Mercaptopurine, in ITP, *1976:* Sept., 973–974
Mercury, embolization, *1977:* Nov., 1363
Mesocaval shunt, for portal hypertension, *1975:* July, 952
Mesothelioma, of liver, *1975:* July, 1011
Metabolic acidosis, renal ammonia production and, *1975:* May, 586, 599, **629–648,** 782–783
glutamine and, *1975:* May, **555–567**
renal carbon dioxide production in, *1975:* May, 511
renal gluconeogenesis and, *1975:* May, 786–788
renal glutaminate and, *1975:* May, 673–675
Metabolic alkalosis, renal ammonia production and, *1975:* May, 586, 591
renal carbon dioxide production in, *1975:* May, 511
renal citrate metabolism in, *1975:* May, 571–575
Metabolic equivalents (METS), for various activities, *1977:* July, 717–720
Metabolism, disorders of, liver disease and, *1975:* July, **919–925**
in pregnancy, *1977:* Jan., **43–66**
inborn errors, gamma-glutamyl cycle and, *1975:* May, 654–656
Metaproterenol, *1977:* Nov., 1244
Methanol extraction residue (MER), as immunomodulator, *1976:* May, **475–488**
Methimazole, for hyperthyroidism in pregnancy, *1975:* Sept., 1095
Methionine, serum, in hepatic encephalopathy, *1975:* July, 938
Methotrexate, hepatotoxicity of, *1975:* July, 905
in acute lymphocytic leukemia, *1976:* Sept., 989
in bronchogenic carcinoma, *1977:* Sept., 985
in non-Hodgkin's lymphomas, *1976:* Sept., 1048
in metastatic breast cancer, *1977:* Sept., 970
in osteosarcoma, *1977:* Sept., 1034
in rheumatic diseases, *1977:* March, 420–421, 430
pulmonary toxicity, *1977:* Nov., 1355
Methoxyflurane, hepatotoxicity of, *1975:* July, 903
Methyl CCNU, in brain tumors, *1977:* Sept., 1049–1050
in gastrointestinal cancer, *1977:* Sept., 993
Methyldopa, *1977:* March, 292; May, 679–680
Methylxanthines, for asthma, *1977:* Nov., 1240–1242
METS, for various activities, *1977:* July, 717–720
Migraine, biofeedback for, *1977:* July, 919
relaxation response in, *1977:* July, 935
Minerals, adolescent requirements, *1975:* Nov., 1335
Minoxidil, *1977:* May, 619, 690
Mitogen bioassay, for thymosin, *1976:* May, 594
Mitomycin C, *1977:* March, 420
in gastrointestinal cancer, *1977:* Sept., 993
in metastatic breast cancer, *1977:* Sept., 969–972
in stomach cancer, *1977:* Sept., 996
Mitral stenosis, in aged, *1976:* Nov., 1068
in pregnancy, *1977:* Jan., 33–35
Mixed leukocyte reaction, in bioassay for thymosin, *1976:* May, 594
Moban. See *Dihydroindolone.*
Mobile intensive/coronary care units, *1976:* March, **283–290**
Mobitz block, *1976:* Jan., 11, 47, 183, 187
Molindone. See *Dihydroindolone.*
Monge's disease, *1977:* Nov., 1285
Monitoring, Holter, *1976:* March, **299–313**
of arrhythmias, computers in, *1976:* March, **291–298**
Monoamine oxidase inhibitors, *1977:* May, 684–685
Monoclonal gammopathy, benign essential, *1975:* March, 384–385

Monocrotaline, *1977:* Nov., 1297
Mood changes, physical disease presenting with, *1977:* July, 730–731
Morphine, pulmonary congestion from, *1977:* Nov., 1324
Mountain sickness, *1977:* Nov., 1322
Mouse leukemia, neuraminidase-treated leukemic cells in, *1977:* Sept., 1085–1088
Movement, disorders of, *1977:* July, 733
Mucopolysaccharidoses, *1975:* July, 921
Mucosal changes, in granulocytopenic patients, *1977:* Sept., 1101
Mumps antigen, in immunotherapy of malignant disease, *1976:* May, 394, 399
Muscular dystrophy, experimental, selenium, *1976:* July, 746
Muscular pulmonary artery, *1977:* Nov., 1280
Mycobacteria, as immunomodulators in treatment of cancer, *1976:* May, 473–474
Mycoplasma pneumoniae pneumonia, *1977:* Nov., 1172–1173
Mycosis fungoides, topical immunotherapy for, *1976:* May, 403–406
Mycotic infection, respiratory, *1977:* Jan., 118
Myeloblast(s), allogeneic, collection of, *1977:* Sept., 1093
  neuraminidase-treated, in leukemia, *1977:* Sept., 1093–1096
Myelofibrosis and myeloid metaplasia, *1976:* Nov., 1267
Myeloproliferative disease, platelet aggregation in, *1976:* Sept., 897–901
Myeloproliferative syndrome, *1976:* Sept., 1001
Myelosuppressive therapy, infection after, *1977:* Sept., **1101–1118**
Myleran. See *Busulfan.*
Myocardial infarction, anticoagulants in, *1976:* Sept., 864
  arrhythmias in, *1976:* March, **233–244**
  electrophysiologic changes with, *1976:* Jan., **49–67**
  in aged, *1976:* Nov., 1064
  in hypertension, *1977:* May, 587–589
  psychological aspects, *1977:* July, **711–721**
Myocardium, trauma to, roentgen signs, *1975:* Jan., 68, 71
Myochrysine (gold sodium thiomalate), *1977:* March, 413
Myxedema. See also *Hypothyroidism.*
  coma, thyroid hormone therapy in, *1975:* Sept., 1160
  iodide-induced, *1975:* Sept., 1080–1082
  pretibial, in Graves' disease, *1975:* Sept., 1180, 1184, 1189
Myxoma, of liver, *1975:* July, 1013

NAPROXEN, *1977:* March, 359, 410
Navane. See *Thiothixine.*
Near drowning, *1977:* Nov., 1330
Neck, carcinoma of, *1975:* March, 405–406, 413–417
Neck (*Continued*)
  carcinoma of, chemoimmunotherapy for, *1976:* May, 449
Necrotizing vasculitis, *1977:* March, 241–260
Neisseria gonorrheae infection, *1977:* Jan., 147
Neomycin, for hepatic encephalopathy, *1975:* July, 941
Neonatal hypothyroidism, thyroid hormone therapy in, *1975:* Sept., 1160
Neonate, hypothyroidism in, *1977:* Jan., 75–77
Neoplastic disease. See also *Carcinoma; Tumor(s);* and specific disorders.
  hypothyroidism with, *1975:* Sept., 1269–1270
Nephrectomy, in renal cell carcinoma, *1975:* March, 297–298
Nephroblastoma, congenital. See *Wilms' tumor.*
Nephrolithiasis, in aged, *1976:* Nov., 1114
  in gout, *1977:* March, 306
Nephroma, mesoblastic, *1977:* Sept., 1068
Nephropathy, of sickle cell disease, *1976:* Sept., 936
Nephrosclerosis, increased blood pressure and, *1977:* May, 612
Nervous system, central, copper deficiency and, *1976:* July, 697–700
  copper toxicity and, *1976:* July, 709
    dysfunction in cancer, *1977:* July, 743–744
    manganese and, *1976:* July, **729–738**
    metastatic lesions, surgical intervention, *1975:* March, **487–494**
    prophylaxis in acute leukemia, *1976:* Sept., 989, 992
  sympathetic, thyroid hormone and, *1975:* Sept., 1123–1125
Neuraminidase, in immune function, *1975:* March, 331
  Vibrio cholerae, in immunotherapy, *1977:* Sept., **1083–1100**
Neuraminidase-modified cells, in therapy of breast cancer, *1976:* May, **551–565**
  in therapy of leukemia, *1976:* May, **539–549**
Neuroblastoma, *1977:* Sept., **1053–1061**
Neuroleptics, *1977:* July, 898–904
Neurologic disorders, *1977:* July, **723–736**
  in aged, *1976:* Nov., **1315–1324**
  in hypertension, *1977:* May, **565–580**
Neuropsychopharmacology, basic principles, *1977:* July, 892–894
Neurosurgery, for pain of cancer, *1975:* March, **481–485**
Newborn. See under *Infant(s).*
Nickel, effect on endocrine function, *1976:* July, 783
Nicking, arteriovenous, retinal, *1977:* May, 549, 550
Niemann-Pick's disease, *1975:* July, 921
Nitrofurantoin (Furadantin, Macrodantin), pulmonary toxicity, *1977:* Nov., 1358
Nitrogen, metabolism, glutamine and, *1975:* May, 667

Nitrogen mustard, for mycosis fungoides, *1976:* May, 403–406
in non-Hodgkin's lymphomas, *1976:* Sept., 1046–1048
Nitrosoureas, *1976:* Sept., 963–964
Nocardiosis, *1977:* Nov., 1178
Nodule(s), rheumatoid, *1977:* March, 218–220
tophaceous, *1977:* March, 305
Noise, hypertension and, *1977:* May, 535–536
Noncardiogenic pulmonary edema, *1977:* Nov., **1319–1337**
Non-ionic diffusion, renal excretion by, *1975:* May, **681–698**
Norpramin. See *Desipramine.*
Nortriptyline (Aventyl), *1977:* July, 895
Novobiocin, liver injury from, *1975:* July, 901
Nutrition, during pregnancy, *1977:* Jan., **3–15**
of adolescents, *1975:* Nov., **1329–1336**

OAT cell carcinoma of lung, *1975:* Jan., 108, 110
Obesity, *1977:* July, **781–796**
hypertension and, *1977:* May, 481
in adolescents, *1975:* Nov., **1507–1516**
pregnancy and, *1977:* Jan., 4–6
Oculocutaneous albinism, *1976:* Sept., 890
Oleate, renal metabolism of, *1975:* May, 511–515
Oligomenorrhea, in adolescents, *1975:* Nov., **1385–1394**
Oligomycin, and renal fatty acid utilization, *1975:* May, 702, 704, 708
Oliguria, in aged, *1976:* Nov., 1112
in hepatocirculatory failure, *1975:* July, 955
Oncology, psychological aspects of, *1977:* July, **737–748**
Oncovin. See *Vincristine.*
Oophorectomy, in metastatic breast cancer, *1975:* March, 426–427
Ophthalmopathy, Graves', *1975:* Sept., 1179–1182, 1184, 1186, 1189
Opiates, abuse, medical complications, *1975:* Nov., 1445–1449
Optic fundus, in hypertension, *1977:* May, **547–564**
Oral contraceptives, for adolescents, *1975:* Nov., 1412–1414
pulmonary hypertension and, *1977:* Nov., 1361
Organic acids, renal excretion by non-ionic diffusion, *1975:* May, **681–698**
Orgasm, *1977:* July, 814
Orthopedic surgery, for rheumatic disease in aged, *1976:* Nov., 1187
Osler-Rendu-Weber syndrome, *1976:* Nov., 1274
Osteoarthritis, *1976:* Nov., 1176
erosive, *1977:* March, 391
roentgen features, *1977:* March, 394, 401–403
Osteogenic sarcoma, chemoimmunotherapy in, *1976:* May, 451
Osteomalacia, cadmium and, *1976:* July, 760
Osteomyelitis, Salmonella, *1976:* Sept., 938
Osteoporosis, *1976:* Nov., **1213–1224**
in rheumatoid arthritis, *1977:* March, 224
Osteosarcoma, *1977:* Sept., **1027–1038**
advances in treatment, *1977:* Sept., 946
Ouabain, and renal fatty acid utilization, *1975:* May, 702, 704, 707–708
Ovary(ies), cancer of, *1977:* Sept., **1001–1012**
chemotherapy, *1975:* March, 406
staging, *1977:* Sept., 947
pubertal changes, *1975:* Nov., 1294
tumors, in adolescents, *1975:* Nov., 1389
Oxazepam, liver disease and, *1975:* July, 891
Oxidative metabolism, renal, *1975:* May, 507–522
Oxisuran, *1977:* March, 421
5-Oxoprolinuria, *1975:* May, 654–655
Oxygen, renal consumption of, *1975:* May, 523–524
therapy, chronic, *1977:* Nov., **1397–1408**
in respiratory failure, *1977:* Nov., 1390
toxicity, *1977:* Nov., 1331
utilization, in pregnancy, *1977:* Jan, 112
Oxygenation, assessment of, *1977:* Nov., 1372–1379
Oxyphenbutazone, *1977:* March, 307, 359
Oxyphenisatin acetate, hepatotoxicity of, *1975:* July, 906

PACEMAKERS, characteristics of, *1976:* March, 353
for tachycardia-bradycardia syndrome, *1976:* Jan., 93–95
in myocardial infarction, *1976:* March, 239, 241
in Wolff-Parkinson-White syndrome, *1976:* Jan., 116
indications and techniques, *1976:* March, **343–367**
new developments in, *1976:* March, **369–384**
Pacemaker cells, ectopic beats generated by, *1976:* Jan., 7–13
Paget's disease, *1975:* March, 474
Pain, *1977:* July, **771–780**
of cancer, neurosurgical treatment, *1975:* March, **481–485**
peptic ulcer and, *1976:* Nov., 1165
Palmitate, renal metabolism of, *1975:* May, 511–515, 525–529
Palmitic acid, renal utilization of, *1975:* May, 699–711
Pancoast tumor, *1975:* Jan., 111
Pancreas, atrophy, experimental, selenium and, *1976:* July, 748
cancer of, *1975:* March, 401; *1977:* Sept., 994–995

Pancreas (*Continued*)
cancer of, pancreatography in, *1975:* March, **239–246**
periampullary, *1975:* March, **309–314**
disease, radiologic approach, *1975:* Jan., **121–143**
radioisotopic examination, *1975:* Jan., 126–127
ultrasound examination, *1975:* Jan., 129–130
Pancreatitis, acute, *1976:* Nov., 1153
in pregnancy, *1977:* Jan., 134
postoperative, *1975:* July, 829
pulmonary infiltrates and, *1977:* Nov., 1329
Pancreatocholangiography, endoscopic, *1975:* Jan., 125–126
Pancreatography, *1975:* March, **239–246**
Panhypopituitarism, familial, *1975:* Sept., 1265
Papanicolaou test, for lung metastases, *1975:* March, 278
Paraesophageal hernia, *1976:* Nov., 1144
Paramedics, in emergency coronary care, *1976:* March, 285
Papilledema, in hypertension, *1977:* May, 559
Paranoid states, in pulmonary disease, *1977:* July, 752
Paraquat, pulmonary reactions, *1977:* Nov., 1362
Parasystole, *1976:* Jan., 15–16, **125–147**
junctional, *1976:* Jan., 25
Parathormone, in bone physiolo y, *1976:* Nov., 1217
Parathyroid disease, hypothyroidism with, *1975:* Sept., 1269
Parkinson's disease, *1976:* Nov., 1317–1321
Paroxysmal atrial fibrillation, in tachycardia-bradycardia syndrome, *1976:* Jan., 81
Paroxysmal atrial tachycardia, *1976:* Jan., 28, 33
electroversion of, *1976:* March, 333
hemodynamic changes, *1976:* Jan., 75
Paroxysmal supraventricular tachycardia, *1976:* Jan., 165
exercise-induced, *1976:* March, 316
Pediculosis, *1975:* Nov., 1479
Pelvic periostitis, *1977:* March, 358
Pendred syndrome, *1975:* Sept., 1266
Penicillamine, *1977:* March, 293, 415
Pentobarbital, liver disease and, *1975:* July, 890
Peptic ulcer, in aged, *1976:* Nov., **1159–1172**
perforated, *1976:* Nov., 1163
Perfusion lung scan, *1977:* Nov., 1212
in thromboembolic disease, *1975:* Jan., 16–26
Periactin. See *Cyproheptadine.*
Periampullary carcinoma, *1975:* March, **309–314**
Periarteritis nodosa, immunosuppressive therapy, *1977:* March, 433
Pericarditis, *1977:* March, 225
in aged, *1976:* Nov., 1072
Pericardium, trauma to, roentgen signs, *1975:* Jan., 65–68
Peripheral vein thrombosis, *1976:* Nov., 1093
Peritonitis, bacterial, in cirrhosis, *1975:* July, **963–981**
Pernicious anemia, in thyroiditis, *1975:* Sept., 1141–1142
Peroxidase defect, *1975:* Sept., 1266
Personality, change, in elderly, *1976:* Nov., 1297–1313
disorders, in adolescents, *1977:* July, 851–852
myocardial infarction and, *1977:* July, 720
Pertofan. See *Desipramine.*
Phagocytosis, stimulation by levamisole, *1976:* May, 526
Pharyngitis, in granulocytopenic patient, *1977:* Sept., 1102
Phenformin, in aged, *1976:* Nov., 1204
Phenobarbital, *1975:* Nov., 1467
liver disease and, *1975:* July, 890
Phenothiazines, *1977:* July, 898–904
Phenoxybenzamine, *1977:* May, 685
Phentolamine, *1977:* May, 685
L-Phenylalanine mustard, in breast cancer, *1977:* Sept., 957–961
in osteosarcoma, *1977:* Sept., 1034
Phenylbutazone, *1977:* March, 307, 359, 408
Pheochromocytoma, *1975:* Sept., 1269
roentgen signs, *1975:* Jan., 196–197
Philadelphia chromosome, *1976:* Sept., 1003
Phlegmasia cerulea dolans, *1976:* Nov., 1098
Photodermatoses, *1975:* Nov., 1478
Physical illness, in adolescence, *1977:* July, 849–851
Pituitary gland, disorders, TRH stimulation in, *1975:* Sept., 1050
fetal, ontogenesis, *1975:* Sept., 1099–1101
function, zinc and, *1976:* July, 785
in regulation of thyroid function, *1975:* Sept., **1045–1053**
Pituitary hormones, lead and, *1976:* July, 782
Pituitary snuff, *1077:* Nov., 1363
Placenta, transfer of thyroid hormones, *1975:* Sept., 1102–1103
Placidyl. See *Ethchlorvynol.*
Platelet(s), aggregation, in disorders of hemostasis, *1976:* Sept., **881–911**
disorders, in aged, *1976:* Nov., 1279
transfusions, *1977:* Sept., 1133–1145
in leukemia, *1975:* March, 370
zinc and, *1976:* July, 801
Pleura, trauma to, roentgen signs, *1975:* Jan., 38–46
Pleural effusions, *1977:* Nov., 1339–1352
Pleural needle biopsy, *1975:* March, 280
Pleurisy, *1977:* March, 225
Plummer's disease, *1975:* Sept., **1203–1215**
thyroidectomy in, *1975:* Sept., 1249
Pneumococcal pneumonia, *1977:* Nov., 1164–1168
Pneumocystis carinii infection, in compromised host, *1977:* Nov., 1179–1180

Pneumomediastinum, *1975:* Jan., 61, 62
Pneumonia(s), bacterial, *1977:* Nov., 1164–1172. See also specific types, as *Pneumococcal pneumonia.*
in aged, *1976:* Nov., 1131–1133
in granulocytopenic patient, *1977:* Sept., 1102
in pregnancy, *1977:* Jan., 117
Pneumonitis, hypersensitivity, *1977:* Nov., 1257
radiation, *1975:* Jan., 48, 49; *1977:* Nov., 1357
Pneumothorax, *1977:* Jan., 124
traumatic, *1975:* Jan., 38–41, 42–43
Polyarteritis nodosa, *1977:* March, 242–248
Polycythemia vera, *1976:* Nov., 1266, 1275
platelet aggregation in, *1976:* Sept., 898
Polymorphonuclear leukocytes, zinc and, *1976:* July, 803
Polymyalgia rheumatica, *1976:* Nov., 1181; *1977:* March, 261, 264–265, 269
Polymyositis, *1976:* Nov., 1182; *1977:* March, **439–451**
immunosuppressive therapy in, *1977:* March, 432
Polymyxin, *1977:* Nov., 1360
Polymyxin B, nephrotoxicity, *1974:* May, 472
Polyposis, familial, carcinoma and, *1975:* March, 347
Portacaval anastomosis, portal hypertension, *1975:* July, 947–949
Portacaval shunt, hepatic encephalopathy and, *1975:* July, 943–944
Portal hypertension, *1975:* July, **945–953**
renal hypoperfusion and, *1975:* July, 958
Portography, *1975:* Jan., 152
Potassium disturbances, in carcinoma, *1975:* March, 453–456
Potassium-loading, renal adaptation to, *1975:* May, **763–769**
PPD, as recall antigen in immunotherapy, *1976:* May, 394, 399–401
PPD creme, for mycosis fungoides, *1976:* May, 407
Prazosin, *1977:* May, 691
Prednisone, *1977:* March, 269, 285, 293, 422, 427–430
in acute lymphocytic leukemia, *1976:* Sept., 988–990
in chronic granulocytic leukemia, *1976:* Sept., 1012
Pre-eclampsia, *1977:* Jan., 96
Preexcitation dysrhythmias, *1976:* Jan., **101–123**
Pregnancy (symposium), *1977:* Jan., **1–201**
in adolescents, *1975:* Nov., 1419–1424
anemia of, *1975:* Nov., 1487
thyroid in, *1975:* Sept., **1089–1098**
Premature beat(s), junctional, *1976:* Jan., 37
ventricular, *1976:* Jan., 37–40
exercise-induced, *1976:* March, 321
in acute myocardial infarction, *1976:* March, 242
Premature ejaculation, *1977:* July, 815
Premature ventricular contractions, relaxation response training in, *1977:* July, 934
Pretibial myxedema, in Graves' disease, *1975:* Sept., 1180, 1184, 1189
Preventive medicine, in geriatrics, *1976:* Nov., 1325–1332
Primidone, *1975:* Nov., 1468
Probenecid, *1977:* March, 308
and renal fatty acid utilization, *1975:* May, 601, 702
sulfonamide diuretics and, *1975:* May, 737, 739–743
Procainamide, electrophysiologic aspects, *1976:* March, 217–219
for arrhythmias, *1976:* March, 224, 227
Procainamide hydrochloride (Pronestyl), pulmonary toxicity, *1977:* Nov., 1364
Procarbazine, C. parvum in therapy with, *1976:* May, 516
in bronchogenic carcinoma, *1977:* Sept., 985
Proctitis, ulcerative, *1977:* Jan., 135
Progesterone, *1977:* Jan., 49
trace metal concentrations and, *1976:* July, 791
Prolactin, *1975:* Nov., 1294
secretion, physiology of, *1977:* Jan., 153
Prolixin. See *Fluphenazine.*
Pronestyl. See *Procainamide hydrochloride.*
Propoxyphene (Darvon), overdose, *1977:* Nov., 1325
Propranolol, *1977:* May, 685–688
electrophysiologic aspects, *1976:* March, 220–222
for arrhythmias, *1976:* March, 224, 227
for hyperthyroidism, *1975:* Sept., 1196–1199
in pregnancy, *1975:* Sept., 1096
in acute myocardial infarction, *1976:* March, 238
Propylthiouracil, for hyperthyroidism in pregnancy, *1975:* Sept., 1095
Prostaglandins, antihypertensive endocrine function and, *1975:* May, **713–733**
Prostate, cancer of, *1976:* Nov., 1244
Protamine sulfate, *1976:* Sept., 858
Protein(s), dietary restrictions of, for hepatic encephalopathy, *1975:* July, 941
requirements, for adolescents, *1975:* Nov., 1332–1333
in pregnancy, *1977:* Jan., 7–8
synthesis, leukocytic endogenous mediator and, *1976:* July, 844
Protein-bound iodine determinations, *1975:* Sept., 1064
Proteinosis, alveolar, pulmonary, *1977:* Nov., 1253
Protriptyline (Vivactil), *1977:* July, 894
Pseudoaneurysm, *1975:* Jan., 72
Pseudodementia, *1977:* July, 863
Pseudogout, *1976:* Nov., 1180
Pseudohypoparathyroidism, *1975:* Sept., 1265
Pseudolymphoma, *1977:* March, 278
Pseudomonas aeruginosa pneumonia, *1977:* Nov., 1168–1170
Psoriatic arthritis, *1977:* March, 339
roentgen features, *1977:* March, 391–393, 398, 400, 401

Psychiatric disorders, in adolescence, *1977:* July, 851–853
in cancer patient, *1977:* July, 743–744
in elderly, *1977:* July, **703–942**
Psychic trigger, in Graves' disease, *1975:*
Psychiatric tigger, in Graves' disease, *1975:* Sept., 1182
Psychological aspects, of acute leukemia in children, *1976:* Sept., 995
Psychomotor seizures, in adolescents, *1975:* Nov., 1462
Psychosis, in elderly, *1977:* July, 863–865
Psychosocial aspects of cancer management, *1977:* Sept., **1147–1155**
Psychotherapy, dynamic, in sexual disorders, *1977:* July, 820
Psychotic disorders, *1977:* July, 734–735
functional, neuroleptics in, *1977:* July, 898–904
Psychotropic drugs, *1977:* July, **891–905**
in elderly, *1976:* Nov., 1308–1314, *1977:* July, 865
Puberty, *1975:* Nov., **1289–1304**
delayed, *1975:* Nov., **1337–1347**
growth and development during, *1975:* Nov., **1305–1317**
regulation of onset, *1975:* Nov., 1299–1301
skin problems with, *1975:* Nov., 1474–1477
Puerperium, cardiovascular problems and, *1977:* Jan., 29–31
hemodynamic changes in, *1977:* Jan., 19–23
Pulmonary. See also *Lung(s).*
Pulmonary alveolar proteinosis, *1977:* Nov., 1253
Pulmonary arteriography, in thromboembolic disease, *1975:* Jan., 26–34
Pulmonary disease (symposium), *1977:* Nov., **1161–1408**
chronic, obstructive, psychological aspects, *1977:* July, **749–758**
Pulmonary drug reactions, *1977:* Nov., **1353–1369**
Pulmonary edema, cadmium and, *1976:* July, 760
noncardiogenic, *1977:* Nov., 1319–1337
vs. respiratory failure, *1976:* Nov., 1128–1129
Pulmonary embolism, *1977:* Nov., **1309–1318**
in aged, *1976:* Nov., 1098–1100
roentgen evaluation, *1975:* Jan., **3–36**
venous thrombosis with, anticoagulant prophylaxis in, *1976:* Sept., 863–864
Pulmonary emphysema. See *Emphysema.*
Pulmonary fibrosis, idiopathic, *1977:* Nov., 1252
Pulmonary function, in sarcoidosis, *1977:* Nov., 1268–1270
tests, in asthma, *1977:* Nov., 1230–1231
Pulmonary heart disease, in aged, *1976:* Nov., 1073
Pulmonary hypertension, *1977:* Nov., 1280–1285, 1290–1304
drug-induced, *1977:* Nov., 1361–1362
in pregnancy, *1977:* Jan., 36
Pulmonary infarctions, in sickle cell disease, *1976:* Sept., 935
thromboembolic disease with, *1975:* Jan., 10–15
Pulmonary infection, *1977:* Nov., **1163–1183**
Pulmonary insufficiency, post-traumatic, *1975:* Jan., 50–52, 53
Pulmonary physiology, *1977:* Nov., **1369–1396**
in aged, *1976:* Nov., 1121
Pulmonary thromboembolic disease, arteriography in, *1975:* Jan., 26–34
roentgen evaluation, *1975:* Jan., **3–36**
Pulmonary vascular disease, *1977:* Nov., 1279–1307
Pulmonary ventilation, *1977:* Jan., 112
Pulsus paradoxicus, in asthma, *1977:* Nov., 1233
Purpura, in aged, *1976:* Nov., 1273
thrombocytopenic, idiopathic, immunosuppressive therapy of, *1976:* Sept., **971–986**
immune, platelet aggregation in, *1976:* Sept., 901–902
Pyarthrosis, *1977:* March, 316, 317
Pyelonephritis, chronic, *1975:* Jan., 206
chronic atrophic, *1977:* May, 613
in pregnancy, *1977:* Jan., 93
Pyrazinamide, *1977:* Nov., 1199, 1200
hepatotoxicity of, *1975:* July, 905
Pyrrolizidine alkaloids, pulmonary hypertension from, *1977:* Nov., 1297–1303
Pyruvate, renal metabolism of, *1975:* May, 547–550
Pyruvate carboxylase, manganese deficiency and, *1976:* July, 719–725

QUINIDINE, electrophysiologic aspects, *1976:* March, 217–219
for arrhythmias, *1976:* March, 224, 227

RADIATION. See also *Roentgen.*
Radiation pneumonitis, *1975:* Jan., 48, 49; *1977:* Nov., 1357
Radiation therapy, C. parvum with, *1976:* May, 516
in acute lymphocytic leukemia, *1976:* Sept., 989, 992
thyroid carcinoma after, *1975:* Sept., 1233–1235
Radioactive iodine therapy, *1975:* Sept., **1217–1220**
Radiospirometry, *1977:* Nov., 1212
Radiotherapy, for lung cancer, *1977:* Nov., 1214
in ovarian cancer, *1977:* Sept., 1006–1007
Ragwort, pulmonary hypertension from, *1977:* Nov., 1296
Raynaud's disease, biofeedback in, *1977:* July, 919
Raynaud's phenomenon, *1977:* March, 292
Recall antigens, *1976:* May, 394
in therapy for skin cancer, *1976:* May, 399–403

Rectum, bleeding from, *1976:* Nov., 1150
carcinoma of, *1975:* March, 347–361; *1976:* Nov., 1247
chemotherapy for, *1975:* March, 401–402
Red cell(s), aplasia, pure, *1976:* Sept., **945–958**
citrate content and permeability, *1975:* May, 575–577
Red cell membrane, hemolytic anemias and, *1976:* Sept., **913–932**
Re-entrant excitation, *1976:* Jan., 23–44
Reiter's syndrome, *1977:* March, 325, 336–338, 356–358, **365–376**
Relatedness, in adolescence, *1977:* July, 843
Relaxation response, *1977:* July, **929–938**
Renal. See also *Kidney.*
Renal artery(ies), fibromuscular disease of, *1977:* May, **623–641**
stenosis of, *1975:* Jan., 182–186; *1977:* May, 613
Renal cadmium, hypertension and, *1976:* July, 764–766
Renal cell carcinoma, *1975:* March, **293–299**
Renal circulation, cardiac arrhythmias and, *1976:* Jan., 75
Renal disease, hypertension and, *1977:* May, **611–622**
in aged, *1976:* Nov., **1105–1119**
in pregnancy, *1977:* Jan., **89–109**
Renal failure, in pregnancy, *1977:* Jan., 102–104
liver disease and, *1975:* July, **955–962**
Renal fibromuscular dysplasia, *1975:* Jan., 178–181
Renal insufficiency, chronic, of aged, *1976:* Nov., 1118
in fulminant hepatic failure, *1975:* July, 928
Renal parenchymal hypertension, *1975:* Jan., 191–192
Renal tubular acidosis, delayed puberty and, *1975:* Nov., 1342
Renal tubular cell, plasma membranes, substrate transport by, *1975:* May, **615–627**
Renal tubular function, in Sjögren's syndrome, *1977:* March, 277
Renin activity, in hypertension, *1977:* May, 618–619, 634
Renin-angiotensin-aldosterone system, *1977:* May, 677
Renin assay, in renovascular hypertension, *1975:* Jan., 187–188
Renotropins, *1975:* May, **771–780**
Renovascular hypertension, *1977:* May, **611–622, 623–641**
abdominal radiography in, *1975:* Jan., 169–192
surgical management, *1977:* May, **643–653**
Reserpine (Sandril; Serpasil), in adolescents, *1975:* Nov., 1381; *1977:* May, 681
in hyperthyroidism, *1975:* Sept., 1195
Resorcinols, *1977:* Nov., 1243
Respiration, in labor and delivery, *1977:* Jan., 115
physiology of, gestational, *1977:* Jan., 111
renal, thyroid hormone and, *1975:* May, 606
Respiratory disease, in pregnancy, *1977:* Jan., **111–128**
obstructive, psychological aspects, *1977:* July, **749–758**
Respiratory distress syndrome, adult, *1977:* Nov., 1322
Respiratory failure, *1977:* Nov., **1369–1396**
acute, in aged, *1976:* Nov., 1127
liver failure and, *1975:* July, 932
Respiratory system, aging and, *1976:* Nov., **1121–1139**
roentgen evaluation, *1975:* Jan., **3–36**
in chest trauma, *1975:* Jan., **37–64**
Respiratory tract infection, *1977:* Nov., **1163–1183**
Reticuloendothelial system, activation by C. parvum, *1976:* May, 513
effect of MER on, *1976:* May, 478
Reticulum cell sarcoma, *1976:* Sept., 1044
intralesional administration of lymphokine preparations, *1976:* May, 411–414
Retinal lesions, in sickle cell disease, *1976:* Sept., 936
Retinopathy, hypertensive, *1977:* May, **547–564**
Rhabdomyosarcoma, *1977:* Sept., 1039
Rheumatic diseases (symposium), *1977:* March, **203–461**
drugs for, hepatotoxicity of, *1975:* July, 903
in elderly, *1976:* Nov., 1173–1189
Rheumatoid arthritis, immunosuppressive therapy in, *1977:* March, 430–432
in aged, *1976:* Nov., 1177
juvenile, in adolescents, *1975:* Nov., 1497–1505
manganese deficiency and, *1976:* July, 730
roentgen features, *1977:* March, 389–392, 394, 395, 397, 401
systemic complications, *1977:* March, **217–228**
Rheumatoid factor, *1977:* March, 217–218, 380
Rheumatoid nodules, *1977:* March, 218–220
Rhizotomy, alcohol, *1975:* March, 481
Rib, fractures, *1975:* Jan., 57–59, 61
Rifampicin, liver injury from, *1085:* July, 901
Rifampin, in tuberculosis, *1977:* Nov., 1193–1194, 1196–1197, 1199
Ristocetin, platelet aggregation response to, *1976:* Sept., 882–884
Roentgen examination, in rheumatic diseases, *1977:* March, **389–404**
Roentgen signs, in diffuse infiltrative lung disease, *1977:* Nov., **1251–1266**
Rotor's syndrome, *1975:* July, 813, 814, 815
Rubella, *1977:* March, 323
in pregnancy, *1977:* Jan., 141

SACROILIAC joints, in ankylosing spondylitis, *1977:* March, 348, 349–352
Sacroiliitis, *1977:* March, 399, 400
Salbutamol, *1977:* Nov., 1244
Salicylates, gastric ulcer and, *1976:* Nov., 1167
ingestion, pulmonary edema with, *1977:* Nov., 1328
renal excretion of, *1975:* May, 684–687
Saligenins, *1977:* Nov., 1243
Salivary gland, in Sjögren's syndrome, *1977:* March, 274–276
Salmonella, osteomyelitis, *1976:* Sept., 938
Sandril. See *Reserpine.*
Sarcoidosis, *1977:* Nov., **1267–1278**
in pregnancy, *1977:* Jan., 123
Sarcoma, osteogenic, chemoimmunotherapy for, *1976:* May, 451
soft tissue, chemotherapy of, *1977:* Sept., **1039–1043**
Scanning, for hepatic metastases, *1975:* March, **247–276**
Schizophrenia, *1977:* July, 777
Scleroderma, *1977:* March, **283–297**
immunosuppressive therapy in, *1977:* March, 432
Screening tests, for neonatal thyroid function, *1975:* Sept., 1104–1106
Seborrheic dermatitis, *1975:* Nov., 1476
Sedatives, hepatic encephalopathy from, *1975:* July, 940
parenchymal liver disease and, *1975:* July, 889–894
Seizures, *1977:* July, 725–729
in adolescents, *1975:* Nov., **1461–1473**
Selenium, essentiality and metabolic functions, *1976:* July, **745–758**
Self-esteem, in acute illness, *1977:* July, 715
Senecio jacobaea, pulmonary hypertension from, *1977:* Nov., 1296
Senility, misdiagnosed, *1977:* July, 856
Septal defects, ventricular, traumatic, *1975:* Jan., 79
Septic arthritis, *1977:* March, 315–320
Serotherapy of malignant disease, *1976:* May, **607–622**
Serpasil. See *Reserpine.*
Serum complement determination, *1977:* March, 382–384
Serum protein determination, *1977:* March, 385
Serum TSH concentration, in primary hypothyroidism, *1975:* Sept., 1048–1049
Sex hormones. See *Androgen; Estrogen.*
Sex steroids, pubertal changes, *1975:* Nov., 1295–1299
Sex therapy, *1977:* July, 822
Sexual activity, after myocardial infarction, *1977:* July, 719–720
Sexual development, delayed, *1975:* Nov., **1337–1347**
female, *1975:* Nov., 1314–1316
male, *1975:* Nov., 1309–1314
psychological, *1977:* July, 816–820
Sexual disorders, treatment of, *1977:* July, **811–823**
Sexual function, in pulmonary disease, *1977:* July, 753–754
Sexual response cycle, *1977:* July, 813–814
Shock, cardiogenic, in aged, *1976:* Nov., 1065
liver dysfunction with, *1975:* July, 826
Shock lung, *1977:* Nov., 1322
Shoulder-hand syndrome, *1976:* Nov., 1184
Shunt(s), cardiovascular, post-traumatic, *1975:* Jan., 71, 78
in dialysis, psychological aspects, *1977:* July, 763
Shunt hyperbilirubinemia syndrome, *1975:* July, 807
Sialic acids, in antigenic expression, *1975:* March, 330, 333, 334
Sick sinus syndrome, *1976:* Jan., 95–96; Nov., 1074
Sickle cell anemia, *1976:* Sept., 926, **933–944**
Sickle cell disease, *1977:* Jan., 172
Sinequan. See *Doxepin.*
Sinoatrial block, *1976:* Jan., 5
Sinoatrial nodal disease, *1976:* Jan., 5
Sinoatrial tachycardia, reciprocating, *1976:* Jan., 28, 34
Sinus arrhythmia(s), *1976:* Jan., 3–5
Sinus bradycardia, hemodynamic changes in, *1976:* Jan., 75
Sinus echo, *1976:* Jan., 25, 28
Sinus parasystole, *1976:* Jan., 130, 132
Sinus rhythm, maintenance, after electroversion, *1976:* March, 338
Sinus tachycardia, pacing techniques for, *1976:* March, 357
Sipple syndrome, *1975:* Sept., 1269
Sjögren's syndrome, *1977:* March, **271–282**
Skin, delayed hypersensitivity reactions, local immunotherapy and, *1976:* May, 389–411
disorders. See also specific disorders, as *Atopic dermatitis.*
in rheumatic diseases. See specific diseases.
in scleroderma, *1977:* March, 291
infection, drug abuse and, *1975:* Nov., 1479
lesions, in granulocytopenic patient, *1977:* Sept., 1102
malignant and premalignant lesions, immunotherapy for, *1976:* May, **389–418**
malignant melanoma, *1975:* March, **301–308**
problems, in adolescents, *1975:* Nov., **1473–1480**
reactions, to BCG injections for cancer, *1976:* May, 504–505
signs of internal malignancy, *1975:* March, **471–479**
ulcers, in aged, *1976:* Nov., 1236
SLE. See *Lupus erythematosus, systemic.*
Sleep disorders, *1977:* July, 728–729
in aged, *1977:* July, 856
Small cell carcinoma of lung, *1975:* Jan., 108, 110
anaplastic, *1977:* Sept., 983, 986

Smell, abnormalities, zinc and, *1976:* July, 679
Smoke inhalation, *1977:* Nov., 1332
Smoking, lung cancer and, *1975:* March, 320; *1977:* Nov., 1205–1206
sudden coronary death and, *1976:* March, 254–259, 262
Smooth muscle antibody, in chronic hepatitis, *1975:* July, 872
Sodium disturbances, in carcinoma, *1975:* March, 449–453
hypertension and, *1977:* May, 479, 490, 617
metabolism, in pregnancy, *1977:* Jan., 12
renal oxidative metabolism and, *1975:* May, 707
renal reabsorption, *1975:* May, 607–609
metabolic support for, *1975:* May, **523–538**
renal transport of, renal oxygen consumption and, *1975:* May, 606
Sodium nitroprusside, *1977:* May, 691
Sodium-potassium adenosine triphosphatase, potassium loading and, *1975:* May, 763–767
thyroid hormone and, *1975:* May, **606–614**; Sept., 1055–1056
Soft tissue sarcoma(s), chemotherapy of, *1977:* Sept., **1039–1043**
Solganol. See *Aurothioglucose.*
Solid tumors, chemotherapy for, *1975:* March, **399–409**
growth kinetics of, *1975:* March, **339–346**
malignant, advances in treatment, *1977:* Sept., **945–951**
Somatic complaints, in elderly, *1977:* July, 862
psychogenic, *1977:* July, 729–730
Somogyi phenomenon, *1975:* Nov., 1354
Spherocytosis, congenital, *1975:* Nov., 1486
hereditary, *1976:* Sept., 922–924
Spine arthropathy, *1977:* March, **347–364**
deformity, in adolescence, *1975:* Nov., 1517–1525
degenerative disease, *1976:* Nov., 1175
metastatic disease, surgery in, *1975:* March, 491–494
Spleen, irradiation, in leukemia, *1976:* Sept., 1007
Splenectomy, for red cell aplasia, *1976:* Sept., 954
in ITP, *1976:* Sept., 977
in leukemia, *1976:* Sept., 1010
Splenomegaly, leukopenia with, *1977:* March, 223
Splenorenal shunt, for portal hypertension, *1975:* July, 952
Spontaneous hypertension, experimental, *1977:* May, **593–609**
Squamous cell carcinoma, immunotherapy in, *1976:* May, 391
of lung, *1975:* Jan., 103, 104, 105
of vulva, local immunotherapy for, *1976:* May, 411
Staphylococcal pneumonia, *1977:* Nov., 1168–1169, 1174
Star, macular, *1977:* May, 555
Stearate, renal metabolism of, *1975:* May, 511–515
Stelazine. See *Trifluoperazine.*
Sterilization, *1977:* Jan., 32
Sternum, fractures, *1975:* Jan., 59
Steroids, gonadal, in hyperthyroidism, *1975:* Sept., **1109–1121**
sex, pubertal changes, *1975:* Nov., 1295–1299
Stomach, cancer, *1977:* Sept., 995–997
chemotherapy for, *1975:* March, 400
ulcer, *1976:* Nov., 1166–1168. See also *Peptic ulcer.*
Stomatitis, aphthous, levamisole for, *1976:* May, 526
Storage pool disease, platelet aggregation studies in, *1976:* Sept., 889–891, 896
Streptococcal infection, in pregnancy, *1977:* Jan., 149
Streptococcal pneumonia, *1977:* Nov., 1164–1169
Streptokinase-streptodornase, as recall antigen in immunotherapy of malignant disease, *1976:* May, 394–399
Streptomycin, for tuberculosis, *1977:* Nov., 1193–1194, 1199
Stress, hypertension and, *1977:* May, 531–535
myocardial infarction and, *1977:* July, 720
onset of illness and, *1977:* July, 825–838
platelet response to, *1976:* Sept., 904–905
relaxation training in, *1977:* July, **929–938**
Stroke, hypertension and, *1977:* May, 475, 527, **565–580**
Struma lymphomatosa, *1975:* Sept., 1166–1171
Subclavian steal syndrome, *1976:* Nov., 1087
Subjunctional escape beat, sequelae, *1976:* Jan., 12–15
Succinimides, *1975:* Nov., 1468
Sudden coronary death, prevention of, *1976:* March, **245–282**
Suicidal risk, in cancer patient, *1977:* July, 745
Suicide, in adolescents, *1975:* Nov., 1434–1436
Sulfasymazine, renal excretion of, *1975:* May, 684–687
Sulfinpyrazone, *1977:* March, 309
Sulfonamide(s), pulmonary reactions to, *1977:* Nov., 1360
Sulfonamide diuretics, *1975:* May, **735–750**
Sulfonylureas, in aged, *1976:* Nov., 1202
Sun, photoallergic reactions to, *1975:* Nov., 1478
Superoxide dismutase, *1976:* July, 690
manganese deficiency and, *1976:* July, 721–725
Supraventricular arrhythmias, drugs for, *1976:* March, 226
exercise-induced, *1976:* March, 316–317
in myocardial infarction, *1976:* March, 240
Supraventricular tachycardias, pacing techniques for, *1976:* March, 354–357

Surgery, jaundice after, *1975:* July, **823–829**
Swallowing, disorders of, in aged, *1976:* Nov., 1141–1144
Sympathetic nervous system, thyroid hormone and, *1975:* Sept., 1123–1125
Syncope, with intraventricular conduction defects, *1976:* Jan., 180–181
Syphilis, in adolescents, *1975:* Nov., 1398–1400
in pregnancy, *1977:* Jan., 145
Systemic lupus erythematosus. See *Lupus erythematosus, systemic.*

TACHYCARDIA(s), atrial, paroxysmal, *1976:* Jan., 28, 33; Sept., 997
ectopic, *1976:* Jan., 7
electrical pacing and, *1976:* March, **343–367**
hypertension and, *1977:* May, 505–506
in pregnancy, *1977:* Jan., 24
in Wolff-Parkinson-White syndrome, *1976:* Jan., 105–109
mechanisms, of, *1976:* March, 343–346
paroxysmal supraventricular, *1976:* Jan., 165
re-entrant, *1976:* Jan., 23–44
sinus, *1976:* Jan., 5
in myocardial infarction, *1976:* March, 239
supraventricular, regional blood flow change, *1976:* Jan., 74
ventricular, *1976:* Jan., 25
hemodynamic changes, *1977:* Jan., 77
in myocardial infarction, *1976:* March, 242
Tachycardia-bradycardia syndrome, *1976:* Jan., **81–99**; March, 352
Tamponade, cardiac, *1975:* Jan., 65, 67, 69
Tangier disease, *1975:* July, 921
Taste, abnormalities, zinc and, *1976:* July, 679
TBG. See *Thyroxine-binding globulin.*
Tegretol. See *Carbamazepine.*
Temporal arteritis, *1977:* March, 265, 269
Teratogenesis, trace elements and, *1976:* July, **771–778**
zinc deficiency and, *1976:* July, 677–678
Teratoma, benign, of liver, *1975:* July, 1011
Terbutaline, *1977:* Nov., 1244
Testis(es), pubertal changes, *1975:* Nov., 1295
Testosterone, in hyperthyroid men, *1975:* Sept., 1114–1117
Tetracyclines, liver disease from, *1975:* July, 899
Thalassemias, *1976:* Sept., 926
in pregnancy, *1977:* Jan., 175–177
Theophylline, *1975:* Nov., 1494; *1977:* Nov., 1240
Thioridazine (Mellaril), *1977:* July, 898
Thio-TEPA, in breast cancer, *1977:* Sept., 955–956
Thiothixine (Navane), *1977:* July, 898
Thiothanzines, *1977:* July, 898–904
Thoracic wall, injuries to, roentgen evaluation, *1975:* Jan., 57–59
Thrombasthenia, Glanzmann's, platelet aggregation studies in, *1976:* Sept., 885–889, 896
Thorazine. See *Chlorpromazine.*
Thrombocythemia, *1976:* Nov., 1275
Thrombocytopenia, *1977:* Jan., 183
neonatal, *1977:* Jan., 178
platelet transfusion for, *1977:* Sept., 1135–1137
Thrombocytopenic purpura, idiopathic, immunotherapy of, *1976:* Sept., **971–986**
Thromboembolic disease, anticoagulants in, *1976:* Sept., **855–869**
in pregnancy, *1977:* Jan., 186
pulmonary, roentgen evaluation, *1975:* Jan., **3–36**
venous, in aged, *1976:* Nov., 1093–1104
Thrombopathy, platelet aggregation studies in, *1976:* Sept., 889, 896
Thrombophlebitis, superficial, *1976:* Nov., 1101
Thrombosis, deep vein, *1976:* Sept., 863; *1977:* Nov., 1313
Thymectomy, immunoregulation and, *1977:* March, 210
Thymoma, red cell aplasia and, *1976:* Sept., 951
Thymosin, immunopotentiating effects, *1976:* May, 592
in immunodeficiency diseases and cancer, *1976:* May, **591–606**
Thyroglobulin synthesis, disorders of, *1975:* Sept., 1266
Thyroid-catecholamine interactions, *1975:* Sept., **1123–1131**
Thyroid disease, in pregnancy, *1977:* Jan., **67–87**
mood changes in, *1977:* July, 730–731
Thyroid dysgenesis, *1975:* Sept., 1267
Thyroid function, catecholamines and, *1975:* Sept., 1128–1129
in pregnancy, *1975:* Sept., **1089–1098**
iodides and, *1975:* Sept., **1075–1088**
lead and, *1976:* July, 781
pituitary and hypothalamus in, *1975:* Sept., **1045–1063**
tests of, *1975:* Sept., **1063–1074**
hormones in, *1975:* Sept., 1153–1155
Thyroid gland, carcinoma of, *1975:* March, **459–470;** Sept., **1233–1246**
in pregnancy, *1975:* Sept., 1091
surgery for, *1975:* Sept., 1252–1257
disorders, anemia in, *1975:* Sept., **1133–1145**
genetic, *1975:* Sept., **1263–1274**
in aged, heart in, *1976:* Nov., 1072
enlargement, *1975:* Sept., **1221–1232**
large autonomous multinodular, *1975:* Sept., 1208–1214
needle biopsy of, *1975:* Sept., 1226–1228
scanning, *1975:* Sept., 1071
surgery, *1975:* Sept., **1247–1261**
Thyroid hormone(s), determinations, *1975:* Sept., 1063–1067

Thyroid hormone(s) (*Continued*)
erythropoiesis and, *1975:* Sept., 1133–1135
in renal energy metabolism, *1975:* May, **605–614**
peripheral action of, *1975:* Sept., **1055–1061**
placental transfer of, *1975:* Sept., 1102–1103
release, iodide inhibition of, *1975:* Sept., 1077
serum levels, in evaluating radioactive iodine therapy, *1975:* Sept., 1219
therapy with, *1975:* Sept., 1147–1162
Thyroid metabolism, inborn errors of, *1975:* Sept., 1266
Thyroid nodule, autonomous functioning, *1975:* Sept., 1204–1208
single, *1975:* Sept., 1223–1225
Thyroid-pituitary axis, evaluation of, *1975:* Sept., 1071
Thyroid-stimulating hormone (TSH), hypothalamic secretion, *1975:* Sept., 1045, 1047–1048
Thyroid storm, *1977:* Jan., 82
Thyroidectomy, *1975:* March, 464–467
iodide-sensitivity after, *1975:* Sept., 1082
Thyroiditis, anemia in, *1975:* Sept., 1141–1142
Hashimoto's. See *Hashimoto's thyroiditis.*
needle biopsy in, *1975:* Sept., 1226
pathogenesis of, *1975:* Sept., **1163–1175**
surgery for, *1975:* Sept., 1259–1260
Thyrotoxicosis, 1268–1269. See also *Hyperthyroidism.*
in pregnancy, *1975:* Sept., 1094–1097
Thyrotoxicosis, *1977:* Jan., 77–83
iodide-induced, *1975:* Sept., 1084
iodide therapy for, *1975:* Sept., 1085–1086
neonatal, *1975:* Sept., 1105–1106
surgery for, *1975:* Sept., 1248–1251
Thyrotropin-releasing hormone, *1975:* Sept., 1045–1047
Thyroxine, *1975:* Sept., 1147–1149
serum concentration, tests of, *1975:* Sept., 1064–1066
in Graves' disease, *1975:* Sept., 1185
Thyroxine-binding globulin, disorders, *1975:* Sept., 1271–1272
in pregnancy, *1975:* Sept., 1089–1090
serum determinations, *1975:* Sept., 1064–1066, 1067–1069
TIC mustard, in neuroblastoma, *1977:* Sept., 1060
Ticarcillin, *1977:* Sept., 1114
Tinea cruris, *1975:* Nov., 1478
Tinea pedis, *1975:* Nov., 1478
Tobramycin, *1977:* Sept., 1114
Tofranil. See *Imipramine.*
Tolazamide, *1976:* Nov., 1205
Tolmetin, *1977:* March, 410
Tophi, *1977:* March, 305
Toxemia of pregnancy, *1977:* Jan., 96
Toxoplasmosis, *1977:* Jan., 140
Trace elements (symposium), *1976:* July, **655–852**
Trace elements (symposium) (*Continued*)
abnormalities, diagnosis of, *1976:* July, **655–660**
Trace metals, hypertension and, *1977:* May, 482
Tracheobronchial obstruction, roentgen evaluation, *1975:* Jan., 54–55
Tranquilizers, hepatic encephalopathy from, *1975:* July, 940
major, *1977:* July, 898–904
Transcatheter (brush) biopsy of lung, *1975:* Jan., 114–115
Transfer factor, in immunotherapy of cancer, *1976:* May, **585–590**
Transfusion, exchange, for fulminant hepatic failure, *1975:* July, 932
granulocyte, *1977:* Sept., **1119–1131**
hepatitis after, *1975:* July, 840–841
passive immunization, *1975:* July, 859
hepatitis B after, *1975:* July, 853
platelet, *1977:* Sept., **1133–1145**
Transplant, bone marrow, infection after, *1977:* Sept., **1101–1118**
renal, hypertension in, *1977:* May, 615
pregnancy and, *1977:* Jan., 105
Trauma, chest, roentgen evaluation, of cardiovascular system, *1975:* Jan., 65–93
of respiratory system, *1975:* Jan., **37–64**
hematuria with, *1975:* Jan., 207–211
Tremor, *1976:* Nov., 1325
Treponema pallidum infection, *1977:* Jan., 145
TRH. See *Thyrotropin-releasing hormone.*
Trichomonas infection, *1975:* Nov., 1402
Tricyclic antidepressants, *1977:* July, 894–896
Trifluoperazine (Stelazine), *1977:* July, 898
Triflupromazine (Vesprin), *1977:* July, 898
Triiodothyronine, *1975:* Sept., 1147–1149
fetal metabolism of, *1975:* Sept., 1101–1102
serum concentration, tests, *1975:* Sept., 1066–1067
Trimethaphan, *1977:* May, 681
TSH. See *Thyroid-stimulating hormone.*
Tuberculosis, *1977:* Nov., **1185–1204**
BCG vaccination for, complications of, *1976:* May, 499–500
in aged, *1976:* Nov., 1135–1138
in pregnancy, *1977:* Jan., 119–121
Tuberculous arthritis, *1977:* March, 322
Tumor-specific antigens, in leukemia, *1976:* Sept., 1022–1026
Tumor(s), benign, of liver, *1975:* July, **995–1013**
growth, enhanced by BCG, *1976:* May, 505
inhibited by levamisole, *1976:* May, 527
hormone-producing, ectopic, *1975:* March, **431–440**
of brain, *1977:* Sept., **1045–1051**
solid, chemoimmunotherapy of, *1976:* May, **441–462**
chemotherapy, *1975:* March, **399–409**
growth kinetics, *1975:* March, **339–346**

Tumor(s) (*Continued*)
solid, immunologic defects in, *1976:* May, 631
malignant, advances in treatment, *1977:* Sept., **945–951**
Tumor Immunotherapy, International Registry of, *1976:* May, **641–648**
Turner's syndrome, *1975:* Nov., 1340–1341
thyroid dysfunction with, *1975:* Sept., 1271

ULCER, peptic, in aged, *1976:* Nov., **1159–1172**
skin, in aged, *1976:* Nov., 1236
ischemic, *1976:* Nov., 1085
leg, in sickle cell disease, *1976:* Sept., 935
Ulcerative colitis, arthritis with, *1977:* March, 338
in pregnancy, *1977:* Jan., 135
Ultrasonography, in diagnosis of gallbladder disease, *1975:* Jan., 127–131
Uremia, platelet dysfunction in, *1976:* Sept., 903
Ureter, carcinoma of, *1975:* Jan., 227
Urethritis, of Reiter's syndrome, *1977:* March, 365
Uricosuric drugs, *1977:* March, 308
Urinalysis, in renal disease of aged, *1976:* Nov., 1107
Urinary calculi, *1975:* Jan., 205–207
Urinary tract, infection and, in aged, *1976:* Nov., 1110, 1231–1235
in pregnancy, *1977:* Jan., 92–96
inflammatory disease, *1975:* Jan., 204–205, 206
tumors of, *1975:* Jan., 217–231
Urine, blood in, radiologic evaluation, *1975:* Jan., **201–232**
light-chain protein, *1977:* March, 384
screening, in pregnancy, *1977:* Jan., 94
Urography, in renovascular hypertension, *1975:* Jan., 170–172
intravenous, in evaluation of hematuria, *1975:* Jan., 202–204
Uterus, cancer of, *1976:* Nov., 1249
Uterine bleeding, dysfunctional, in adolescents, *1975:* Nov., 1391–1393
Uveitis, in ankylosing spondylitis, *1977:* March, 353

VALIUM. See *Diazepam.*
Varicella-zoster infection, in acute leukemia, *1976:* Sept., 993
Varicose veins, *1976:* Nov., 1102
Vascular disease, pulmonary, *1977:* Nov., 1279–1307
Vascular system, integrity of, copper and, *1976:* July, 692
Vasculitis, necrotizing, *1977:* March, 241–260
rheumatoid, *1977:* March, 220–221
Vaso-occlusive crises, in sickle cell disease, *1976:* Sept., 934–935
Velban. See *Vinblastine.*
Venereal disease, in adolescents, *1975:* Nov., **1395–1405**
Venous insufficiency, chronic, *1976:* Nov., 1101
Venous thromboembolic disease, in aged, *1976:* Nov., 1093–1104
Ventilation, assisted, in respiratory failure, *1977:* Nov., 1391
Ventilation, measurement of, *1977:* Nov., 1379–1382
pulmonary, *1977:* Jan., 112
Ventilation lung scan, *1975:* Jan., 25
Ventilation/perfusion relationships in asthma, *1974:* Jan., 107–108
Ventricular arrhythmias, electroversion of, *1976:* March, 333
exercise-induced, *1976:* March, 319
in myocardial infarction, *1976:* March, 235
pacing techniques for, *1976:* March, 350
Ventricular fibrillation, *1976:* Jan., 3
Ventricular parasystole, *1976:* Jan., 133, 134, 137–140
Ventricular premature beat, *1976:* Jan., 25, 37–40
exercise-induced, *1976:* March, 321
in acute myocardial infarction, *1976:* March, 242
in elderly, *1976:* Nov., 1075
Ventricular tachycardia, *1976:* Jan., 25, 40–44
decelerating, *1976:* Jan., 39
hemodynamic changes, *1976:* Jan., 77
in myocardial infarction, *1976:* March, 242
Verapamil, electrophysiologic aspects, *1976:* March, 222
Vesprin. See *Trifluprom azine*
Vibrio cholerae neuraminidase, *1975:* March, 333–334
in immunotherapy, *1977:* Sept., **1083–1100**
of breast cancer, *1976:* May, **551–565**
of leukemia, *1976:* May, **539–549**
Vinblastine (Velban), in ITP, *1976:* Sept., 975
in metastatic breast cancer, *1977:* Sept., 969–972
Vincristine (Oncovin), *1977:* March, 420
in acute lymphocytic leukemia in children, *1976:* Sept., 988–990
in bronchogenic carcinoma, *1977:* Sept., 985
in chronic granulocytic leukemia, *1976:* Sept., 1012
in ITP, *1976:* Sept., 975
in metastatic breast cancer, *1977:* Sept., 969–972
in non-Hodgkin's lymphomas, *1976:* Sept., 1047, 1048–1051
in Wilms' tumor, *1977:* Sept., 1067
Viomycin, *1977:* Nov., 1200
Viral arthritis, *1977:* March, 323–325
Viral hepatitis, *1977:* March, 324
active and passive immunization, *1975:* July, **857–862**
cholestasis in, *1975:* July, 818
chronic, *1975:* July, **863–867**
fulminant hepatic failure after, *1975:* July, 927

Viral hepatitis (*Continued*)
in pregnancy, *1977:* Jan., 132
postoperative, *1975:* July, 825
type A, *1975:* July, **831–834**
type B, antigens and antibodies, *1975:* July, **849–855**
epidemiology, *1975:* July, **835–842**
immune serum globulin and, *1975:* July, 861
in drug abuser, *1975:* July, **843–848**
Viral pneumonia, *1977:* Nov., 1173–1175
Vitamin(s), in pregnancy, *1977:* Jan., 11
Virus, autoimmune diseases and, *1977:* March, **205–215**
immunoregulation and, *1977:* March, 212
Vision, disturbed, in temporal arteritis, *1977:* March, 265, 267
Vitamin(s), metabolism, in hyperthyroidism, *1975:* Sept., 1140–1141
requirements for adolescents, *1975:* Nov., 1333–1334
Vitamin B_{12}, deficiency, *1975:* Nov., 1484
serum abnormalities in leukemia, *1976:* Sept., 1005
Vitamin D, bone physiology and, *1976:* Nov., 1217
Vitamin K, blood coagulation and, *1976:* Sept., 859, 861
Von Willebrand's disease, platelet aggregation in, *1976:* Sept., 891–892, 896
Vivactil. See *Protriptyline.*
Vulva, squamous cell carcinoma of, local immunotherapy for, *1976:* May, 411

WATER, conservation, renal metabolism and, *1975:* May, 523
excess, in carcinoma, *1975:* March, 449–451
Wegener's granulomatosis, *1977:* March, 256, 434
Weight, changes in adolescence, *1975:* Nov., 1308–1309
gain, during pregnancy, *1977:* Jan., 4–6
Wenckebach phenomenon, *1976:* Jan., 183
Westermark sign, *1975:* Jan., 7, 10
Wheezing, in asthma, *1977:* Nov., 1232
Wilms' tumor, *1977:* Sept., **1061–1068**
Wilson's disease, *1975:* July, 924; *1976:* July, 656, 659, 708–710
Wiskott-Aldrich syndrome, platelet aggregation in, *1976:* Sept., 890
Wolff-Chaikoff effect, *1975:* Sept., 1076
Wolff-Parkinson-White syndrome, *1976:* Jan., 40, 42, **101–123**
concealment in, *1976:* Jan., 164
pacing techniques for, *1976:* March, 358–361
Wolman's disease, *1975:* July, 921
Work environment, hypertension and, *1977:* May, **531–545**
Workmen's Compensation, in hypertension, *1977:* May, 539
Wound healing, zinc and, *1976:* July, 678

XANTHINE oxidase inhibitors, in gout, *1977:* March, 30
Xenon-133 radiospirometry, *1977:* Nov., 1212
Xeroderma pigmentosum, DNCB immunotherapy for, *1976:* May, 397–399

YERSINIOSIS, *1977:* March, 338

ZARONTIN. See *Ethosuximide.*
Zenker diverticulum, *1976:* Nov., 1143
Zinc, abnormalities, clinical and nutritional aspects, *1976:* July, **675–685**
diagnosis of, *1976:* July, **655–660**
biochemistry of, *1976:* July, **661–674**
deficiency, congenital anomalies and, *1976:* July, 773–775
endocrine effects of, *1976:* July, 781
drug metabolism and, *1976:* July, 816–818
effect on cells and biomembranes, *1976:* July, **799–812**
effect on endocrine function, *1976:* July, 785
metabolism, infection and, *1976:* July, 839–840
toxicity, *1976:* July, 680
Zollinger-Ellison syndrome, *1976:* Nov., 1161